

# Expression of specific chemokines and chemokine receptors of multiple sclerosis patients

Journal of Clinical Investigation

103, 807-815

DOI: [10.1172/jci5150](https://doi.org/10.1172/jci5150)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The potential for targeting CD4+CD25+ regulatory T cells in the treatment of multiple sclerosis in humans. , 2005, , 133-151.		1
2	CXC and CC Chemokine Receptors on Coronary and Brain Endothelia. <i>Molecular Medicine</i> , 1999, 5, 795-805.	1.9	127
3	Chemokine Regulation of Immune-mediated Demyelinating Disease. <i>ILAR Journal</i> , 1999, 40, 183-189.	1.8	3
4	Sentries at the gate: chemokines and the blood-brain barrier. <i>Journal of NeuroVirology</i> , 1999, 5, 623-634.	1.0	37
5	Chemokine receptors and virus entry in the central nervous system. <i>Journal of NeuroVirology</i> , 1999, 5, 643-658.	1.0	71
6	CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1 $\alpha$ and IP-10 are expressed in demyelinating brain lesions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 6873-6878.	3.3	825
7	Interfering with chemokine networks – the hope for new therapeutics. <i>Current Opinion in Chemical Biology</i> , 1999, 3, 407-417.	2.8	71
8	Chemokines, chemokine receptors and renal disease. <i>Kidney International</i> , 1999, 56, 347-348.	2.6	11
9	Role of chemokines in the regulation of Th1/Th2 and autoimmune encephalomyelitis. <i>Journal of Clinical Immunology</i> , 1999, 19, 273-279.	2.0	39
10	Mechanisms of inflammation in MS tissue: adhesion molecules and chemokines. <i>Journal of Neuroimmunology</i> , 1999, 98, 57-68.	1.1	152
11	Molecular pathogenesis of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 1999, 100, 252-259.	1.1	106
12	Chemokine modulation of matrix metalloproteinase and TIMP production in adult rat brain microglia and a human microglial cell line in vitro. <i>Glia</i> , 1999, 28, 183-189.	2.5	118
13	Recent developments in modulating chemokine networks. <i>Expert Opinion on Therapeutic Patents</i> , 1999, 9, 1471-1489.	2.4	15
14	Chemokines in the CNS: plurifunctional mediators in diverse states. <i>Trends in Neurosciences</i> , 1999, 22, 504-512.	4.2	335
15	The pathology of multiple sclerosis and its evolution. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 1999, 354, 1635-1640.	1.8	71
16	Aberrant T cell migration toward RANTES and MIP-1 $\alpha$ in patients with multiple sclerosis: Overexpression of chemokine receptor CCR5. <i>Brain</i> , 2000, 123, 1874-1882.	3.7	81
17	Differential induction of chemokines in human microglia by type i and ii interferons. , 2000, 29, 273-280.		67
18	Fractalkine modulates TNF- $\alpha$ secretion and neurotoxicity induced by microglial activation. , 2000, 29, 305-315.		323

#	ARTICLE	IF	CITATIONS
19	Distinct patterns of stimulus-inducible chemokine mRNA accumulation in human fetal astrocytes and microglia. , 2000, 30, 74-81.		93
20	Interleukin-1 $\beta$ -induced expression of monocyte chemotactic protein-1 in the rabbit retina: An in situ and immunohistochemical study. , 2000, 30, 279-289.		10
21	Increased numbers of CCR5+ interferon- $\gamma$ - and tumor necrosis factor- $\gamma$ -secreting T lymphocytes in multiple sclerosis patients. <i>Annals of Neurology</i> , 2000, 47, 269-273.	2.8	92
22	The role of B cells and autoantibodies in multiple sclerosis. <i>Annals of Neurology</i> , 2000, 47, 694-706.	2.8	236
23	Macrophage inflammatory protein-1 $\alpha$ (MIP-1 $\alpha$ ), MIP-1 $\beta$ , and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions. <i>Clinical and Experimental Immunology</i> , 2000, 122, 257-263.	1.1	99
24	Single nucleotide polymorphisms in the coding regions of human CXC-chemokine receptors CXCR1, CXCR2 and CXCR3. <i>Genes and Immunity</i> , 2000, 1, 330-337.	2.2	29
25	Cytokine gene therapy of autoimmune demyelination revisited using herpes simplex virus type-1-derived vectors. <i>Gene Therapy</i> , 2000, 7, 1087-1093.	2.3	27
26	Experimental approaches to analysis of immune dysregulation in human allergic disease. <i>Immunopharmacology</i> , 2000, 48, 283-290.	2.0	3
27	Interleukin-1 $\beta$ induction of the chemokine RANTES promoter in the human astrocytoma line CH235 requires both constitutive and inducible transcription factors. <i>Journal of Neuroimmunology</i> , 2000, 105, 78-90.	1.1	38
28	RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon- $\beta$ . <i>Journal of Neuroimmunology</i> , 2000, 107, 100-107.	1.1	60
29	Expression of the $\beta$ -chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. <i>Journal of Neuroimmunology</i> , 2000, 108, 192-200.	1.1	203
30	Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer's disease. <i>Journal of Neuroimmunology</i> , 2000, 108, 227-235.	1.1	243
31	Cytokines and immunity in multiple sclerosis: the dual signal hypothesis. <i>Journal of Neuroimmunology</i> , 2000, 109, 3-9.	1.1	60
32	Sequential expression of chemokines in experimental autoimmune neuritis. <i>Journal of Neuroimmunology</i> , 2000, 110, 121-129.	1.1	75
33	The chemokine receptor CCR2 is involved in macrophage recruitment to the injured peripheral nervous system. <i>Journal of Neuroimmunology</i> , 2000, 110, 177-185.	1.1	142
34	Modulation of experimental autoimmune encephalomyelitis: effect of altered peptide ligand on chemokine and chemokine receptor expression. <i>Journal of Neuroimmunology</i> , 2000, 110, 195-208.	1.1	93
35	Interferon- $\beta$ treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon- $\gamma$ and interleukin-4. <i>Journal of Neuroimmunology</i> , 2000, 111, 86-92.	1.1	67
36	CCR5 $\beta$ 32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2000, 102, 98-106.	1.1	154

#	ARTICLE	IF	CITATIONS
37	Chemokines and their receptors in neurobiology: perspectives in physiology and homeostasis. <i>Journal of Neuroimmunology</i> , 2000, 104, 92-97.	1.1	119
38	CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. <i>Immunogenetics</i> , 2000, 51, 281-288.	1.2	111
39	Regulation of Th1 and Th2 immune responses by chemokines. <i>Seminars in Immunopathology</i> , 2000, 22, 329-344.	4.0	10
40	CXC chemokine receptor 3 expression on CD34+hematopoietic progenitors from human cord blood induced by granulocyte-macrophage colony-stimulating factor: chemotaxis and adhesion induced by its ligands, interferon $\gamma$ -inducible protein 10 and monokine induced by interferon $\gamma$ . <i>Blood</i> , 2000, 96, 1230-1238.	0.6	42
41	Chemokine expression in Th1 cell-induced lung injury: prominence of IFN- $\gamma$ -inducible chemokines. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2000, 279, L592-L599.	1.3	45
42	Leukocyte Homing to Synovium. , 2000, 3, 133-167.		12
43	Identification and Characterization of a Potent, Selective, and Orally Active Antagonist of the CC Chemokine Receptor-1. <i>Journal of Biological Chemistry</i> , 2000, 275, 19000-19008.	1.6	177
44	Adenovirus Vector-Induced Expression of the C-X-C Chemokine IP-10 Is Mediated through Capsid-Dependent Activation of NF- $\kappa$ B. <i>Journal of Virology</i> , 2000, 74, 3941-3947.	1.5	134
45	Cutting Edge: The T Cell Chemoattractant IFN-Inducible Protein 10 Is Essential in Host Defense Against Viral-Induced Neurologic Disease. <i>Journal of Immunology</i> , 2000, 165, 2327-2330.	0.4	249
46	Reduced Chemokine and Chemokine Receptor Expression in Spinal Cords of TCR BV8S2 Transgenic Mice Protected Against Experimental Autoimmune Encephalomyelitis with BV8S2 Protein. <i>Journal of Immunology</i> , 2000, 164, 3924-3931.	0.4	34
47	Transcriptional Analysis of Multiple Sclerosis Brain Lesions Reveals a Complex Pattern of Cytokine Expression. <i>Journal of Immunology</i> , 2000, 165, 6576-6582.	0.4	145
48	IFN- $\gamma$ Shapes Immune Invasion of the Central Nervous System Via Regulation of Chemokines. <i>Journal of Immunology</i> , 2000, 164, 2759-2768.	0.4	285
49	Macrophage Inflammatory Protein-2 and KC Induce Chemokine Production by Mouse Astrocytes. <i>Journal of Immunology</i> , 2000, 165, 4015-4023.	0.4	62
50	CXCR3 Expression and Activation of Eosinophils: Role of IFN- $\gamma$ -Inducible Protein-10 and Monokine Induced by IFN- $\gamma$ . <i>Journal of Immunology</i> , 2000, 165, 1548-1556.	0.4	147
51	Induction of the Chemokines Interleukin-8 and IP-10 by Human Immunodeficiency Virus Type 1 Tat in Astrocytes. <i>Journal of Virology</i> , 2000, 74, 9214-9221.	1.5	167
52	Therapeutic Potential of Phosphodiesterase-4 and -3 Inhibitors in Th1-Mediated Autoimmune Diseases. <i>Journal of Immunology</i> , 2000, 164, 1117-1124.	0.4	96
53	The Murine Chemokine CXCL11 (IFN-Inducible T Cell $\chi$ Chemoattractant) Is an IFN- $\gamma$ - and Lipopolysaccharide- Inducible Glucocorticoid-Attenuated Response Gene Expressed in Lung and Other Tissues During Endotoxemia. <i>Journal of Immunology</i> , 2000, 164, 6322-6331.	0.4	81
54	Experimental Autoimmune Encephalomyelitis on the SJL Mouse: Effect of $\gamma$ T Cell Depletion on Chemokine and Chemokine Receptor Expression in the Central Nervous System. <i>Journal of Immunology</i> , 2000, 164, 2120-2130.	0.4	82

#	ARTICLE	IF	CITATIONS
55	A Central Role for CD4+ T Cells and RANTES in Virus-Induced Central Nervous System Inflammation and Demyelination. <i>Journal of Virology</i> , 2000, 74, 1415-1424.	1.5	234
57	Expression of multiple functional chemokine receptors and monocyte chemoattractant protein-1 in human neurons. <i>Neuroscience</i> , 2000, 97, 591-600.	1.1	202
58	Pathogenetic role of autoantibodies in neurological diseases. <i>Trends in Neurosciences</i> , 2000, 23, 317-327.	4.2	138
59	IP-10 Is Critical for Effector T Cell Trafficking and Host Survival in <i>Toxoplasma gondii</i> Infection. <i>Immunity</i> , 2000, 12, 483-494.	6.6	267
60	RANTES: a new prostaglandin dependent endogenous pyrogen in the rat. <i>Neuropharmacology</i> , 2000, 39, 2505-2513.	2.0	28
61	A search for susceptibility genes in multiple sclerosis. <i>Molecular Biology</i> , 2000, 34, 561-577.	0.4	7
62	Chemokine receptor antagonism as a new therapy for multiple sclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 1079-1097.	1.9	41
63	Chemokines and chemokine receptors in the pathogenesis of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2000, 6, 3-13.	1.4	71
64	Chapter 17. Chemokines: Targets for novel therapeutics. <i>Annual Reports in Medicinal Chemistry</i> , 2000, 35, 191-200.	0.5	7
65	Chemokines regulate lymphocyte homing to the intestinal mucosa. <i>Gastroenterology</i> , 2001, 120, 291-294.	0.6	33
66	T Cell Effector Subsets: Extending the Th1/Th2 Paradigm. <i>Advances in Immunology</i> , 2001, 78, 233-266.	1.1	47
67	CXCR3 and CCR5 Ligands in Rheumatoid Arthritis Synovium. <i>Clinical Immunology</i> , 2001, 98, 39-45.	1.4	316
68	CCR1+/CCR5+ Mononuclear Phagocytes Accumulate in the Central Nervous System of Patients with Multiple Sclerosis. <i>American Journal of Pathology</i> , 2001, 159, 1701-1710.	1.9	238
69	In vivo stability of human chemokine and chemokine receptor expression. <i>Human Immunology</i> , 2001, 62, 668-678.	1.2	13
70	The chemokine system: novel broad-spectrum therapeutic targets. <i>Current Opinion in Pharmacology</i> , 2001, 1, 417-424.	1.7	42
71	Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. <i>Trends in Molecular Medicine</i> , 2001, 7, 115-121.	3.5	558
72	Factors modifying the migration of lymphocytes across the blood-brain barrier. <i>International Immunopharmacology</i> , 2001, 1, 2043-2062.	1.7	63
74	Distinct chemokine receptor and cytokine expression profile in secondary progressive MS. <i>Neurology</i> , 2001, 57, 1371-1376.	1.5	77

#	ARTICLE	IF	CITATIONS
75	Two subsets of dendritic cells are present in human cerebrospinal fluid. <i>Brain</i> , 2001, 124, 480-492.	3.7	219
76	Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. <i>Blood</i> , 2001, 98, 3554-3561.	0.6	227
77	Investigating Chemokines and Chemokine Receptors in Patients With Multiple Sclerosis. <i>Archives of Neurology</i> , 2001, 58, 1975.	4.9	97
78	Chemokines and viral diseases of the central nervous system. <i>Advances in Virus Research</i> , 2001, 56, 127-173.	0.9	23
79	The role of chemokines and chemokine receptors in CNS inflammation. <i>Progress in Brain Research</i> , 2001, 132, 533-544.	0.9	35
80	Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. <i>Current Opinion in Neurology</i> , 2001, 14, 259-269.	1.8	111
81	TNF $\alpha$ production by CD4 <sup>+</sup> T cells predicts long-term increase in lesion load on MRI in MS. <i>Neurology</i> , 2001, 57, 1129-1131.	1.5	22
82	Hypoxia induces expression of the chemokines monocyte chemoattractant protein-1 (MCP-1) and IL-8 in human dermal fibroblasts. <i>Clinical and Experimental Immunology</i> , 2001, 123, 36-41.	1.1	78
83	The heat shock response reduces myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in mice. <i>Journal of Neurochemistry</i> , 2001, 77, 568-579.	2.1	32
84	Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis. <i>European Journal of Neurology</i> , 2001, 8, 665-672.	1.7	103
85	CXCR3 expression in human central nervous system diseases. <i>Neuropathology and Applied Neurobiology</i> , 2001, 27, 127-138.	1.8	80
86	Differential release of $\beta$ -chemokines in serum and CSF of patients with relapsing-remitting multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2001, 104, 88-91.	1.0	40
87	Selective CC chemokine receptor expression by central nervous system-infiltrating encephalitogenic T cells during experimental autoimmune encephalomyelitis. <i>Journal of Neuroscience Research</i> , 2001, 66, 705-714.	1.3	50
88	17 $\beta$ -estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis. <i>Journal of Neuroscience Research</i> , 2001, 65, 529-542.	1.3	125
89	Ischemia-induced neuronal expression of the microglia attracting chemokine secondary lymphoid-tissue chemokine (SLC). <i>Glia</i> , 2001, 34, 121-133.	2.5	126
90	Upregulation of transcription factors controlling MHC expression in multiple sclerosis lesions. <i>Glia</i> , 2001, 36, 68-77.	2.5	82
91	Immune function of microglia. <i>Glia</i> , 2001, 36, 165-179.	2.5	1,126
92	Inflammation in the nervous system: The human perspective. <i>Glia</i> , 2001, 36, 235-243.	2.5	90

#	ARTICLE	IF	CITATIONS
93	Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. <i>Annals of Neurology</i> , 2001, 49, 650-658.	2.8	98
94	Complex immunomodulatory effects of interferon- $\beta$ in multiple sclerosis include the upregulation of T helper 1-associated marker genes. <i>Annals of Neurology</i> , 2001, 50, 349-357.	2.8	171
95	Chemokine Regulation of Normal and Pathologic Immune Responses. <i>Stem Cells</i> , 2001, 19, 388-396.	1.4	107
96	Annotated References by Year. , 2001, , 651-770.		0
97	Chemokines and Their Receptors in the Central Nervous System. <i>Frontiers in Neuroendocrinology</i> , 2001, 22, 147-184.	2.5	348
98	The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. <i>Journal of Clinical Immunology</i> , 2001, 21, 81-92.	2.0	155
99	Inflammation in the central nervous system in multiple sclerosis: The role of chemokines and their receptors. <i>Inflammopharmacology</i> , 2001, 9, 23-33.	1.9	1
100	Chemokine Expression and Viral Infection of the Central Nervous System: Regulation of Host Defense and Neuropathology. <i>Immunologic Research</i> , 2001, 24, 111-120.	1.3	17
101	HIV in the CNS: Pathogenic relationships to systemic HIV disease and other CNS diseases. <i>Journal of NeuroVirology</i> , 2001, 7, 85-96.	1.0	19
102	Chemokines and central nervous system disorders. <i>Journal of NeuroVirology</i> , 2001, 7, 493-500.	1.0	24
103	Multiple Sclerosis: Current Pathophysiological Concepts. <i>Laboratory Investigation</i> , 2001, 81, 263-281.	1.7	193
104	Chemokines and disease. <i>Nature Immunology</i> , 2001, 2, 108-115.	7.0	1,293
105	Lymphocyte traffic control by chemokines. <i>Nature Immunology</i> , 2001, 2, 123-128.	7.0	1,115
106	RANTES promotes growth and survival of human first-trimester forebrain astrocytes. <i>Nature Cell Biology</i> , 2001, 3, 150-157.	4.6	78
107	Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1 $\alpha$ by interferon- $\beta$ . <i>Journal of Neuroimmunology</i> , 2001, 112, 174-180.	1.1	84
108	Multiple sclerosis: Genomic rewards. <i>Journal of Neuroimmunology</i> , 2001, 113, 171-184.	1.1	123
109	Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling. <i>Journal of Neuroimmunology</i> , 2001, 114, 207-212.	1.1	120
110	In vivo neutralization of endogenous brain fractalkine increases hippocampal TNF $\alpha$ and 8-isoprostane production induced by intracerebroventricular injection of LPS. <i>Journal of Neuroimmunology</i> , 2001, 115, 135-143.	1.1	85

#	ARTICLE	IF	CITATIONS
111	Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. <i>Journal of Neuroimmunology</i> , 2001, 115, 192-198.	1.1	158
112	Induction of selected chemokines in glial cells infected with Theiler's virus. <i>Journal of Neuroimmunology</i> , 2001, 117, 166-170.	1.1	56
113	Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. <i>Journal of Neurochemistry</i> , 2001, 77, 132-145.	2.1	188
114	Selective Immunointervention in Autoimmune Diseases: Lessons from Multiple Sclerosis. <i>Journal of Chemotherapy</i> , 2001, 13, 219-234.	0.7	22
115	Expression of chemokine receptors in vernal keratoconjunctivitis. <i>British Journal of Ophthalmology</i> , 2001, 85, 1357-1361.	2.1	38
116	Expression of Mig (Monokine Induced by Interferon- $\hat{1}^3$ ) Is Important in T Lymphocyte Recruitment and Host Defense Following Viral Infection of the Central Nervous System. <i>Journal of Immunology</i> , 2001, 166, 1790-1795.	0.4	143
117	CXCL10 (IFN- $\hat{1}^3$ -Inducible Protein-10) Control of Encephalitogenic CD4+ T Cell Accumulation in the Central Nervous System During Experimental Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2001, 166, 7617-7624.	0.4	247
118	Neutralization of the Chemokine CXCL10 Reduces Inflammatory Cell Invasion and Demyelination and Improves Neurological Function in a Viral Model of Multiple Sclerosis. <i>Journal of Immunology</i> , 2001, 167, 4091-4097.	0.4	202
119	Depletion of CCR5-Expressing Cells with Bispecific Antibodies and Chemokine Toxins: A New Strategy in the Treatment of Chronic Inflammatory Diseases and HIV. <i>Journal of Immunology</i> , 2001, 166, 2420-2426.	0.4	40
120	Expression and Characterization of the Chemokine Receptors CCR2 and CCR5 in Mice. <i>Journal of Immunology</i> , 2001, 166, 4697-4704.	0.4	387
121	Microglial chemokines and chemokine receptors. <i>Progress in Brain Research</i> , 2001, 132, 525-532.	0.9	27
122	Expression and Modulation of IFN- $\hat{1}^3$ -Inducible Chemokines (IP-10, Mig, and I-TAC) in Human Brain Endothelium and Astrocytes: Possible Relevance for the Immune Invasion of the Central Nervous System and the Pathogenesis of Multiple Sclerosis. <i>Journal of Interferon and Cytokine Research</i> , 2002, 22, 631-640.	0.5	68
123	Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 10276-10281.	3.3	250
124	A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. <i>Brain</i> , 2002, 125, 1450-1461.	3.7	1,078
125	Differentiation of Human CD8+ T Cells from a Memory to Memory/Effector Phenotype. <i>Journal of Immunology</i> , 2002, 168, 5538-5550.	0.4	201
126	Leukocyte Infiltration, But Not Neurodegeneration, in the CNS of Transgenic Mice with Astrocyte Production of the CXC Chemokine Ligand 10. <i>Journal of Immunology</i> , 2002, 169, 1505-1515.	0.4	78
127	Morphine Regulates Gene Expression of $\hat{1}^{\pm}$ - and $\hat{1}^2$ -Chemokines and Their Receptors on Astroglial Cells Via the Opioid $\hat{1}^{\frac{1}{4}}$ Receptor. <i>Journal of Immunology</i> , 2002, 169, 3589-3599.	0.4	105
128	IFN- $\hat{1}^3$ -Inducible Protein 10 (IP-10; CXCL10)-Deficient Mice Reveal a Role for IP-10 in Effector T Cell Generation and Trafficking. <i>Journal of Immunology</i> , 2002, 168, 3195-3204.	0.4	971



#	ARTICLE	IF	CITATIONS
129	Targeting the Function of IFN- $\hat{I}^3$ -Inducible Protein 10 Suppresses Ongoing Adjuvant Arthritis. <i>Journal of Immunology</i> , 2002, 169, 2685-2693.	0.4	126
130	IFN- $\hat{I}^3$ -Inducible T Cell $\hat{I}^{\pm}$ Chemoattractant Is a Potent Stimulator of Normal Human Blood T Lymphocyte Transendothelial Migration: Differential Regulation by IFN- $\hat{I}^3$ and TNF- $\hat{I}^{\pm}$ . <i>Journal of Immunology</i> , 2002, 168, 6420-6428.	0.4	65
131	Plasmid DNA Encoding IFN- $\hat{I}^3$ -Inducible Protein 10 Redirects Antigen-Specific T Cell Polarization and Suppresses Experimental Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2002, 168, 5885-5892.	0.4	108
132	Mouse Hepatitis Virus Infection of the Central Nervous System: Chemokine-Mediated Regulation of Host Defense and Disease. <i>Viral Immunology</i> , 2002, 15, 261-272.	0.6	55
133	Chemokine Expression Patterns Differ within Anatomically Distinct Regions of the Genital Tract during <i>Chlamydia trachomatis</i> Infection. <i>Infection and Immunity</i> , 2002, 70, 1538-1546.	1.0	63
134	The Ribonuclease Protection Assay: A Powerful Tool for the Veterinary Pathologist. <i>Veterinary Pathology</i> , 2002, 39, 2-9.	0.8	19
135	Chemokine receptors in the brain: their role in HIV infection and pathogenesis. <i>Aids</i> , 2002, 16, 1709-1730.	1.0	44
136	Methylprednisolone Acts on Peripheral Blood Mononuclear Cells and Endothelium in Inhibiting Migration Phenomena in Patients With Multiple Sclerosis. <i>Archives of Neurology</i> , 2002, 59, 774.	4.9	43
137	The CXC Chemokine Murine Monokine Induced by IFN- $\hat{I}^3$ (CXC Chemokine Ligand 9) Is Made by APCs, Targets Lymphocytes Including Activated B Cells, and Supports Antibody Responses to a Bacterial Pathogen In Vivo. <i>Journal of Immunology</i> , 2002, 169, 1433-1443.	0.4	120
138	Expression of chemokines in cerebrospinal fluid and serum of patients with chronic inflammatory demyelinating polyneuropathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 73, 320-323.	0.9	32
139	The Chemokine System in Neuroinflammation: An Update. <i>Journal of Infectious Diseases</i> , 2002, 186, S152-S156.	1.9	125
140	Expression of chemokine receptors in the different clinical forms of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2002, 8, 390-395.	1.4	36
141	Chemokines and chemokine receptors in leukocyte trafficking. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2002, 283, R7-R28.	0.9	572
142	The chemokine receptor CCR5 deletion mutation is associated with MS in HLA-DR4 $\hat{I}^{\pm}$ positive Russians. <i>Neurology</i> , 2002, 59, 1652-1655.	1.5	35
143	Selective suppression of chemokine receptor CXCR3 expression by interferon- $\beta$ 1a in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2002, 8, 104-107.	1.4	32
144	Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E). <i>Multiple Sclerosis Journal</i> , 2002, 8, 295-298.	1.4	55
145	Expression of interferon-gamma-inducible protein-10 in human endometrial stromal cells. <i>Molecular Human Reproduction</i> , 2002, 8, 176-180.	1.3	22
146	G-CSF Therapy of Ongoing Experimental Allergic Encephalomyelitis Via Chemokine- and Cytokine-Based Immune Deviation. <i>Journal of Immunology</i> , 2002, 168, 2011-2019.	0.4	115

#	ARTICLE	IF	CITATIONS
147	Activation of p38 and ERK Signaling during Adenovirus Vector Cell Entry Lead to Expression of the C-X-C Chemokine IP-10. <i>Journal of Virology</i> , 2002, 76, 1559-1568.	1.5	123
148	MIG $\alpha$ differential gene expression in mouse brain endothelial cells. <i>NeuroReport</i> , 2002, 13, 9-14.	0.6	26
149	Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. <i>Brain</i> , 2002, 125, 823-834.	3.7	139
150	Expression of the Chemokine Receptors CCR4, CCR5, and CXCR3 by Human Tissue-Infiltrating Lymphocytes. <i>American Journal of Pathology</i> , 2002, 160, 347-355.	1.9	241
151	CD40-CD40L Interactions Induce Chemokine Expression by Human Microglia. <i>American Journal of Pathology</i> , 2002, 160, 559-567.	1.9	86
152	Experimental Autoimmune Encephalomyelitis: CC Chemokine Receptor Expression by Trafficking Cells. <i>Journal of Autoimmunity</i> , 2002, 19, 175-181.	3.0	40
153	IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease. <i>Journal of the Neurological Sciences</i> , 2002, 195, 41-46.	0.3	92
154	Gelatinase B, PECAM-1 and MCP-3 gene polymorphisms in Belgian multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2002, 200, 43-48.	0.3	19
155	Mechanisms of demyelination and tissue destruction in multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2002, 104, 168-171.	0.6	57
156	The CXCR3 Binding Chemokine IP-10/CXCL10: Structure and Receptor Interactions. <i>Biochemistry</i> , 2002, 41, 10418-10425.	1.2	130
157	Bystander CD8 T Cell-Mediated Demyelination After Viral Infection of the Central Nervous System. <i>Journal of Immunology</i> , 2002, 169, 1550-1555.	0.4	69
158	Reduced Expression of Th1-Associated Chemokine Receptors on Peripheral Blood Lymphocytes at Diagnosis of Type 1 Diabetes. <i>Diabetes</i> , 2002, 51, 2474-2480.	0.3	79
159	Differential mechanisms of action of interferon- $\beta$ and glatiramer acetate in MS. <i>Neurology</i> , 2002, 59, 802-808.	1.5	234
160	$\beta$ T Cells in Multiple Sclerosis: Chemokine and Chemokine Receptor Expression. <i>Clinical Immunology</i> , 2002, 103, 309-316.	1.4	22
161	Statins as immunomodulators. <i>Neurology</i> , 2002, 59, 990-997.	1.5	207
162	Interactions between opioid and chemokine receptors: heterologous desensitization. <i>Cytokine and Growth Factor Reviews</i> , 2002, 13, 209-222.	3.2	87
163	A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis. <i>Clinical Therapeutics</i> , 2002, 24, 1998-2021.	1.1	39
164	Functional expression of CXCR3 in cultured mouse and human astrocytes and microglia. <i>Neuroscience</i> , 2002, 112, 487-497.	1.1	99

#	ARTICLE	IF	CITATIONS
165	Microglial Chemokines and Chemokine Receptors. , 2002, , 289-299.		3
166	Activation of Group III Metabotropic Glutamate Receptors Inhibits the Production of RANTES in Glial Cell Cultures. <i>Journal of Neuroscience</i> , 2002, 22, 5403-5411.	1.7	79
167	Pertussis Toxin-Induced Reversible Encephalopathy Dependent on Monocyte Chemoattractant Protein-1 Overexpression in Mice. <i>Journal of Neuroscience</i> , 2002, 22, 10633-10642.	1.7	63
168	The role of perivascular and meningeal macrophages in experimental allergic encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2002, 122, 1-8.	1.1	98
169	Chemokine receptor expression on B cells and effect of interferon- $\beta$ in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2002, 122, 125-131.	1.1	34
170	GRO $\alpha$ /KC, a chemokine receptor CXCR2 ligand, can be a potent trigger for neuronal ERK1/2 and PI-3 kinase pathways and for tau hyperphosphorylation—a role in Alzheimer's disease?. <i>Journal of Neuroimmunology</i> , 2002, 122, 55-64.	1.1	94
171	Interferon $\beta$ -1b modulates MCP-1 expression and production in relapsingâ€“remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2002, 123, 170-179.	1.1	25
172	Interferon- $\beta$ treatment alters peripheral blood monocytes chemokine production in MS patients. <i>Journal of Neuroimmunology</i> , 2002, 126, 205-212.	1.1	46
173	Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. <i>Journal of Neuroimmunology</i> , 2002, 127, 59-68.	1.1	231
174	Chemokine receptor expression on MBP-reactive T cells: CXCR6 is a marker of IFN $\gamma$ -producing effector cells. <i>Journal of Neuroimmunology</i> , 2002, 127, 96-105.	1.1	32
175	Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. <i>Journal of Neuroimmunology</i> , 2002, 130, 10-21.	1.1	112
176	Phagocytotic removal of apoptotic, inflammatory lymphocytes in the central nervous system by microglia and its functional implications. <i>Journal of Neuroimmunology</i> , 2002, 130, 1-9.	1.1	48
177	Expression of chemokine receptor CXCR3 on cerebrospinal fluid T-cells is related to active MRI lesion appearance in patients with relapsingâ€“remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2002, 131, 186-190.	1.1	36
178	Chemokine receptors associated with immunity within and outside the central nervous system in early relapsingâ€“remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2002, 133, 184-192.	1.1	18
179	VIP and PACAP down-regulate CXCL10 (IP-10) and up-regulate CCL22 (MDC) in spleen cells. <i>Journal of Neuroimmunology</i> , 2002, 133, 81-94.	1.1	37
180	Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2002, 133, 225-232.	1.1	34
181	Inflammation in multiple sclerosis: the good, the bad, and the complex. <i>Lancet Neurology</i> , The, 2002, 1, 499-509.	4.9	146
182	Neutralization of IFN-inducible protein 10/CXCL10 exacerbates experimental autoimmune encephalomyelitis. <i>European Journal of Immunology</i> , 2002, 32, 1784.	1.6	88

#	ARTICLE	IF	CITATIONS
183	Effects of cytokine deficiency on chemokine expression in CNS of mice with EAE. <i>Journal of Neuroscience Research</i> , 2002, 67, 680-688.	1.3	34
184	Involvement of the interferon- $\gamma$ -induced T cell-attracting chemokines, interferon- $\gamma$ -inducible 10-kd protein (CXCL10) and monokine induced by interferon- $\gamma$ (CXCL9), in the salivary gland lesions of patients with Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2002, 46, 2730-2741.	6.7	204
185	RANTES stimulates inflammatory cascades and receptor modulation in murine astrocytes. <i>Glia</i> , 2002, 39, 19-30.	2.5	54
186	The relative number of macrophages/microglia expressing macrophage colony-stimulating factor and its receptor decreases in multiple sclerosis lesions. <i>Glia</i> , 2002, 40, 121-129.	2.5	27
187	Differential intracellular expression of CCR5 and chemokines in multiple sclerosis subtypes. <i>Journal of Neurology</i> , 2002, 249, 576-583.	1.8	30
188	Interferon- $\beta$ activates multiple signaling cascades in primary human microglia. <i>Journal of Neurochemistry</i> , 2002, 81, 1361-1371.	2.1	71
189	Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. <i>Journal of Neurochemistry</i> , 2002, 82, 1311-1329.	2.1	274
190	Elevated expression of CCR5 by myeloid (CD11c + ) blood dendritic cells in multiple sclerosis and acute optic neuritis. <i>Clinical and Experimental Immunology</i> , 2002, 127, 519-526.	1.1	51
191	T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking. <i>Clinical and Experimental Immunology</i> , 2002, 129, 510-518.	1.1	136
192	Dendritic cells, chemokine receptors and autoimmune inflammatory diseases. <i>Immunology and Cell Biology</i> , 2002, 80, 497-505.	1.0	106
193	Inflammation and therapeutic vaccination in CNS diseases. <i>Nature</i> , 2002, 420, 879-884.	13.7	246
194	Chemokine receptors: multifaceted therapeutic targets. <i>Nature Reviews Immunology</i> , 2002, 2, 106-115.	10.6	662
195	CXC Chemokine Receptors in the Central Nervous System: Role in Cerebellar Neuromodulation and Development. <i>Journal of NeuroVirology</i> , 2002, 8, 559-572.	1.0	58
196	Expression of CCR2, CCR5, and CXCR3 by CD4+ T Cells is Stable During a 2-Year Longitudinal Study but Varies Widely Between Individuals. <i>Journal of NeuroVirology</i> , 2003, 9, 291-299.	1.0	13
197	Adenovirus-Mediated Expression of CXCL10 in the Central Nervous System Results in T-Cell Recruitment and Limited Neuropathology. <i>Journal of NeuroVirology</i> , 2003, 9, 315-324.	1.0	17
198	Chemokine and chemokine receptor expression during experimental autoimmune uveoretinitis in mice. <i>Investigative Ophthalmology and Visual Science</i> , 2003, 44, 111-115.		41
200	Crystal Structures of Oligomeric Forms of the IP-10/CXCL10 Chemokine. <i>Structure</i> , 2003, 11, 521-532.	1.6	70
201	Multiple sclerosis in the Japanese population. <i>Lancet Neurology</i> , 2003, 2, 117-127.	4.9	382

#	ARTICLE	IF	CITATIONS
202	Cytokines and chemokines in neuro-Behçet's disease compared to multiple sclerosis and other neurological diseases. <i>Journal of Neuroimmunology</i> , 2003, 145, 127-134.	1.1	82
203	Câ€C chemokine receptor 2 gene polymorphism in Japanese patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2003, 145, 135-138.	1.1	39
204	Monocyte chemoattractant protein 1 and chemokine receptor CCR2 productions in Guillainâ€Barré© syndrome and experimental autoimmune neuritis. <i>Journal of Neuroimmunology</i> , 2003, 134, 118-127.	1.1	64
205	Regulation of chemokine receptor expression in human microglia and astrocytes. <i>Journal of Neuroimmunology</i> , 2003, 136, 84-93.	1.1	199
206	IL-12 dependent/IFNÎ³ independent expression of CCR5 by myelin-reactive T cells correlates with encephalitogenicity. <i>Journal of Neuroimmunology</i> , 2003, 137, 109-116.	1.1	35
207	The development of clinical activity in relapsingâ€remitting MS is associated with a decrease of FasL mRNA and an increase of Fas mRNA in peripheral blood. <i>Journal of Neuroimmunology</i> , 2003, 138, 123-131.	1.1	17
208	Interferon-Î²1a does not reduce expression of CCR5 and CXCR3 on circulating T cells. <i>Journal of Neuroimmunology</i> , 2003, 141, 150-154.	1.1	11
209	Cytokine regulation of MCP-1 expression in brain and retinal microvascular endothelial cells. <i>Journal of Neuroimmunology</i> , 2003, 142, 1-9.	1.1	72
210	Effector stage CC chemokine receptor-1 selective antagonism reduces multiple sclerosis-like rat disease. <i>Journal of Neuroimmunology</i> , 2003, 142, 75-85.	1.1	36
211	Chemokine receptors in inflammation: an overview. <i>Journal of Immunological Methods</i> , 2003, 273, 3-13.	0.6	151
212	Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes. <i>Glia</i> , 2003, 41, 371-381.	2.5	147
213	Astrocytes are the major intracerebral source of macrophage inflammatory protein-3/CCL20 in relapsing experimental autoimmune encephalomyelitis and in vitro. <i>Glia</i> , 2003, 41, 290-300.	2.5	105
214	Differential effects of Th1 and Th2 lymphocyte supernatants on human microglia. <i>Glia</i> , 2003, 42, 36-45.	2.5	35
215	Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation. <i>European Journal of Immunology</i> , 2003, 33, 2927-2936.	1.6	82
216	Promoter polymorphism of IL-10 and severity of multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2003, 108, 396-400.	1.0	56
217	Evidence favoring the involvement of CC chemokine receptor (CCR) 5 in T-lymphocyte accumulation in optic neuritis. <i>Acta Neurologica Scandinavica</i> , 2003, 107, 221-227.	1.0	6
218	Concentrations of Interferon-gamma-Induced Protein-10 (IP-10), an Antiangiogenic Substance, are Decreased in Peritoneal Fluid of Women with Advanced Endometriosis. <i>American Journal of Reproductive Immunology</i> , 2003, 50, 60-65.	1.2	43
219	Chemokine receptors on infiltrating leucocytes in inflammatory pathologies of the central nervous system (CNS). <i>Neuropathology and Applied Neurobiology</i> , 2003, 29, 584-595.	1.8	52

#	ARTICLE	IF	CITATIONS
220	Multiple sclerosis: a study of chemokine receptors and regulatory T cells in relation to MRI variables. <i>European Journal of Neurology</i> , 2003, 10, 529-535.	1.7	28
221	Immune parameters associated with early treatment effects of high-dose intravenous methylprednisolone in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2003, 216, 61-66.	0.3	24
222	Chemokines and their receptors in the CNS: expression of CXCL12/SDF-1 and CXCR4 and their role in astrocyte proliferation. <i>Toxicology Letters</i> , 2003, 139, 181-189.	0.4	88
223	CC Chemokine Receptor 8 in the Central Nervous System Is Associated with Phagocytic Macrophages. <i>American Journal of Pathology</i> , 2003, 162, 427-438.	1.9	59
224	Unraveling the Chemistry of Chemokine Receptor Ligands. <i>Chemical Reviews</i> , 2003, 103, 3733-3752.	23.0	55
225	Complement component anaphylatoxins upregulate chemokine expression by human astrocytes. <i>FEBS Letters</i> , 2003, 537, 17-22.	1.3	46
226	Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. <i>Brain Research Bulletin</i> , 2003, 61, 347-355.	1.4	108
227	The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). <i>Seminars in Immunology</i> , 2003, 15, 23-32.	2.7	374
228	Strategies for chemokine antagonists as therapeutics. <i>Seminars in Immunology</i> , 2003, 15, 57-65.	2.7	89
229	Structure-Function Relationship between the Human Chemokine Receptor CXCR3 and Its Ligands. <i>Journal of Biological Chemistry</i> , 2003, 278, 289-295.	1.6	166
230	Functional Expression of Chemokine Receptor CCR5 on CD4 + T Cells during Virus-Induced Central Nervous System Disease. <i>Journal of Virology</i> , 2003, 77, 191-198.	1.5	60
231	Longitudinal study of chemokine receptor expression on peripheral lymphocytes in multiple sclerosis: CXCR3 upregulation is associated with relapse. <i>Multiple Sclerosis Journal</i> , 2003, 9, 189-198.	1.4	36
232	Inhibition of Interferon (IFN) $\beta$ -induced Jak-STAT1 Activation in Microglia by Vasoactive Intestinal Peptide. <i>Journal of Biological Chemistry</i> , 2003, 278, 27620-27629.	1.6	73
233	Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation. <i>Journal of Leukocyte Biology</i> , 2003, 73, 771-780.	1.5	146
234	Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. <i>Journal of Leukocyte Biology</i> , 2003, 73, 584-590.	1.5	159
235	CC Chemokines Mediate Leukocyte Trafficking into the Central Nervous System during Murine Neurocysticercosis: Role of $\beta$ 1 T Cells in Amplification of the Host Immune Response. <i>Infection and Immunity</i> , 2003, 71, 2634-2642.	1.0	50
236	Differential Responses to IFN- $\alpha$ Subtypes in Human T Cells and Dendritic Cells. <i>Journal of Immunology</i> , 2003, 171, 5255-5263.	0.4	104
237	Endothelial inflammation: the role of differential expression of N-deacetylase/N-sulphotransferase enzymes in alteration of the immunological properties of heparan sulphate. <i>Journal of Cell Science</i> , 2003, 116, 3591-3600.	1.2	95



#	ARTICLE	IF	CITATIONS
238	Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 689-712.	1.9	32
239	Human cerebrospinal fluid central memory CD4+T cells: Evidence for trafficking through choroid plexus and meninges via P-selectin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 8389-8394.	3.3	486
240	Perforin-Dependent Brain-Infiltrating Cytotoxic CD8+ T Lymphocytes Mediate Experimental Cerebral Malaria Pathogenesis. <i>Journal of Immunology</i> , 2003, 170, 2221-2228.	0.4	267
241	Inhibition of IFN- $\gamma$ -Inducible Protein-10 Abrogates Colitis in IL-10 <sup>-/-</sup> Mice. <i>Journal of Immunology</i> , 2003, 171, 1401-1406.	0.4	142
242	Immunoregulatory Role of Ocular Macrophages: The Macrophages Produce RANTES to Suppress Experimental Autoimmune Uveitis. <i>Journal of Immunology</i> , 2003, 171, 2652-2659.	0.4	52
243	CXCR3 and Heparin Binding Sites of the Chemokine IP-10 (CXCL10). <i>Journal of Biological Chemistry</i> , 2003, 278, 17066-17074.	1.6	83
244	CXCR3 Is Induced Early on the Pathway of CD4+ T Cell Differentiation and Bridges Central and Peripheral Functions. <i>Journal of Immunology</i> , 2003, 171, 2812-2824.	0.4	83
245	Chapter 7 Pathology and Pathogenesis of Multiple Sclerosis. <i>Blue Books of Practical Neurology</i> , 2003, 27, 93-113.	0.1	0
246	CX <sub>3</sub> CL1 and CX <sub>3</sub> CR1 Expression in Human Brain Tissue: Noninflammatory Control versus Multiple Sclerosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2003, 62, 899-907.	0.9	72
247	Oligodendroglial-derived stress signals recruit microglia in vitro. <i>NeuroReport</i> , 2003, 14, 1001-1005.	0.6	7
248	Oligodendroglial-derived stress signals recruit microglia in vitro. <i>NeuroReport</i> , 2003, 14, 1001-1005.	0.6	8
249	CXCR3-mediated chemotaxis of human T cells is regulated by a Gi- and phospholipase C $\alpha$ -dependent pathway and not via activation of MEK/p44/p42 MAPK nor Akt/PI-3 kinase. <i>Blood</i> , 2003, 102, 1959-1965.	0.6	161
250	Chemokine Expression by Glial Cells Directs Leukocytes to Sites of Axonal Injury in the CNS. <i>Journal of Neuroscience</i> , 2003, 23, 7922-7930.	1.7	434
251	Chemokines and chemokine receptors in autoimmune encephalomyelitis as a model for central nervous system inflammatory disease regulation. <i>Frontiers in Bioscience - Landmark</i> , 2004, 9, 1500.	3.0	29
252	Chemokine network in multiple sclerosis: role in pathogenesis and targeting for future treatments. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 439-453.	1.4	18
253	Antibody Targeting of the CC Chemokine Ligand 5 Results in Diminished Leukocyte Infiltration into the Central Nervous System and Reduced Neurologic Disease in a Viral Model of Multiple Sclerosis. <i>Journal of Immunology</i> , 2004, 172, 4018-4025.	0.4	126
254	Influence of C C R5 $\Delta$ 32 polymorphism on multiple sclerosis susceptibility and disease course. <i>Multiple Sclerosis Journal</i> , 2004, 10, 149-152.	1.4	42
255	Allergic humans are hypo-responsive to CXCR3 chemokines in a Th1 immunity-promoting loop. <i>FASEB Journal</i> , 2004, 18, 1-19.	0.2	83

#	ARTICLE	IF	CITATIONS
256	Optic neuritis: chemokine receptor CXCR3 and its ligands. <i>British Journal of Ophthalmology</i> , 2004, 88, 1146-1148.	2.1	10
257	RANTES: a genetic risk marker for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004, 10, 536-539.	1.4	41
258	Increased Adhesion Molecule and Chemokine Receptor Expression on CD8+T Cells Trafficking to Cerebrospinal Fluid in HIV Infection. <i>Journal of Infectious Diseases</i> , 2004, 189, 2202-2212.	1.9	73
259	Anti-TNF Therapy Modulates the Phenotype of Peripheral Blood CD4+T Cells in Patients with Posterior Segment Intraocular Inflammation. , 2004, 45, 170.		59
260	Efficient T-Cell Surveillance of the CNS Requires Expression of the CXC Chemokine Receptor 3. <i>Journal of Neuroscience</i> , 2004, 24, 4849-4858.	1.7	88
261	Expression of Th1/Th2-Related Chemokine Receptors on Peripheral T Cells and Correlation with Clinical Disease Activity in Patients with Multiple Sclerosis. <i>European Neurology</i> , 2004, 52, 162-168.	0.6	39
262	Steroid Therapy Altered Serum Levels of CCL2 and CCL5 Chemokines in Multiple Sclerosis Patients during Relapse. <i>European Neurology</i> , 2004, 52, 237-241.	0.6	14
263	CCR2 expressing CD4+ T lymphocytes are preferentially recruited to the ileum in Crohn's disease. <i>Gut</i> , 2004, 53, 1287-1294.	6.1	63
264	Interference with Heparin Binding and Oligomerization Creates a Novel Anti-Inflammatory Strategy Targeting the Chemokine System. <i>Journal of Immunology</i> , 2004, 173, 5776-5785.	0.4	147
265	VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells. <i>FASEB Journal</i> , 2004, 18, 1453-1455.	0.2	99
266	Reduced Expression of Chemokine Receptors on Peripheral Blood Lymphocytes in Patients with Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2004, 99, 1111-1121.	0.2	26
267	Role of Microglia in Central Nervous System Infections. <i>Clinical Microbiology Reviews</i> , 2004, 17, 942-964.	5.7	590
268	Distinct roles for IP-10/CXC L10 in three animal models, Theiler's virus infection, EA E, and MHV infection, for multiple sclerosis: implication of differing roles for IP-10. <i>Multiple Sclerosis Journal</i> , 2004, 10, 26-34.	1.4	79
269	I-TAC/CXCL11 is a natural antagonist for CCR5. <i>Journal of Leukocyte Biology</i> , 2004, 76, 701-708.	1.5	49
270	Increased circulating and intrahepatic T-cell-specific chemokines in chronic hepatitis C: relationship with the type of virological response to peginterferon plus ribavirin combination therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 551-562.	1.9	39
271	Chemokine CCL2 and chemokine receptor CCR2 in early active multiple sclerosis. <i>European Journal of Neurology</i> , 2004, 11, 445-449.	1.7	79
272	Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine. <i>Acta Neurologica Scandinavica</i> , 2004, 109, 390-392.	1.0	54
273	Chemokine receptors and early activation markers in acute anterior uveitis. <i>Acta Ophthalmologica</i> , 2004, 82, 179-183.	0.4	6



#	ARTICLE	IF	CITATIONS
274	Expression and Regulation of the Chemokine Receptor CXCR3 on Lymphocytes from Normal and Inflammatory Bowel Disease Mucosa. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 778-788.	0.9	30
275	Regulation of RANTES/CCL5 expression in human astrocytes by interleukin-1 and interferon-beta. <i>Journal of Neurochemistry</i> , 2004, 90, 297-308.	2.1	53
276	Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN- $\beta$ production of CD8+ T cells in secondary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2004, 146, 189-198.	1.1	45
277	CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2004, 149, 182-186.	1.1	71
278	Acute exposure to CXC chemokine ligand 10, but not its chronic astroglial production, alters synaptic plasticity in mouse hippocampal slices. <i>Journal of Neuroimmunology</i> , 2004, 150, 37-47.	1.1	50
279	Alterations in chemokine expression following Theiler's virus infection and restraint stress. <i>Journal of Neuroimmunology</i> , 2004, 151, 103-115.	1.1	30
280	Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2004, 152, 126-139.	1.1	62
281	15-Deoxy- $\Delta^2$ (12,14)-PGJ2 inhibits astrocyte IL-1 signaling: inhibition of NF- $\kappa$ B and MAP kinase pathways and suppression of cytokine and chemokine expression. <i>Journal of Neuroimmunology</i> , 2004, 153, 132-142.	1.1	15
282	CXCR3 marks CD4+ memory T lymphocytes that are competent to migrate across a human brain microvascular endothelial cell layer. <i>Journal of Neuroimmunology</i> , 2004, 153, 150-157.	1.1	68
283	The chemokine CXCL10 modulates excitatory activity and intracellular calcium signaling in cultured hippocampal neurons. <i>Journal of Neuroimmunology</i> , 2004, 156, 74-87.	1.1	81
284	Is damage in central nervous system due to inflammation?. <i>Autoimmunity Reviews</i> , 2004, 3, 251-260.	2.5	101
285	Chemokines and Glial Cells: A Complex Network in the Central Nervous System. <i>Neurochemical Research</i> , 2004, 29, 1017-1038.	1.6	183
286	Recent neuropathological findings in MS? implications for diagnosis and therapy. <i>Journal of Neurology</i> , 2004, 251, IV2-5.	1.8	36
287	What do we know about the mechanism of action of disease-modifying treatments in MS?. <i>Journal of Neurology</i> , 2004, 251, v12-v29.	1.8	67
289	Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2004, 109, 342-347.	1.0	40
290	Interferon-inducible protein 10/CXCL10 is increased in the cerebrospinal fluid of patients with central nervous system lupus. <i>Arthritis and Rheumatism</i> , 2004, 50, 3731-3732.	6.7	49
291	Expression of CCR7 in multiple sclerosis: Implications for CNS immunity. <i>Annals of Neurology</i> , 2004, 55, 627-638.	2.8	235
292	Induction of glial L-CCR mRNA expression in spinal cord and brain in experimental autoimmune encephalomyelitis. <i>Glia</i> , 2004, 46, 84-94.	2.5	37

#	ARTICLE	IF	CITATIONS
293	Adenosine A3 receptor-induced CCL2 synthesis in cultured mouse astrocytes. <i>Glia</i> , 2004, 46, 410-418.	2.5	89
294	Regulation of neuroinflammation: The role of CXCL10 in lymphocyte infiltration during autoimmune encephalomyelitis. <i>Journal of Cellular Biochemistry</i> , 2004, 92, 213-222.	1.2	44
295	Chemokine Monokine Induced by IFN- $\beta$ /CXC Chemokine Ligand 9 Stimulates T Lymphocyte Proliferation and Effector Cytokine Production. <i>Journal of Immunology</i> , 2004, 172, 7417-7424.	0.4	108
296	Immunotherapeutic approaches in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2004, 223, 13-24.	0.3	35
297	Cellular Damage and Repair in Multiple Sclerosis. , 2004, , 733-762.		10
298	Macrophage brain infiltration in experimental autoimmune encephalomyelitis is not completely compromised by suppressed T-cell invasion: in vivo magnetic resonance imaging illustration in effective anti-VLA-4 antibody treatment. <i>Multiple Sclerosis Journal</i> , 2004, 10, 540-548.	1.4	44
299	A1 Adenosine Receptor Upregulation and Activation Attenuates Neuroinflammation and Demyelination in a Model of Multiple Sclerosis. <i>Journal of Neuroscience</i> , 2004, 24, 1521-1529.	1.7	297
300	Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients. <i>Clinical Immunology</i> , 2004, 111, 38-46.	1.4	18
301	Increased Th1 activity in patients with coronary artery disease. <i>Cytokine</i> , 2004, 26, 131-137.	1.4	74
302	Spinal cord molecular profiling provides a better understanding of Amyotrophic Lateral Sclerosis pathogenesis. <i>Brain Research Reviews</i> , 2004, 45, 213-229.	9.1	33
303	Brain microglia and blood-derived macrophages: molecular profiles and functional roles in multiple sclerosis and animal models of autoimmune demyelinating disease. <i>Brain Research Reviews</i> , 2004, 46, 261-281.	9.1	205
304	Monocyte chemoattractant protein-1 and macrophage inflammatory protein-2 are involved in both excitotoxin-induced neurodegeneration and regeneration. <i>Experimental Cell Research</i> , 2004, 297, 197-211.	1.2	93
305	Decreased CD14+CCR2+ monocytes in active multiple sclerosis. <i>Neuroscience Letters</i> , 2004, 363, 187-189.	1.0	12
306	IFN- $\gamma$ -1a Treatment and Reestablishment of Th1 Regulation in MS Patients. <i>Clinical Neuropharmacology</i> , 2004, 27, 258-269.	0.2	9
307	Acute Disseminated Encephalomyelitis in Childhood: Epidemiologic, Clinical and Laboratory Features. <i>Pediatric Infectious Disease Journal</i> , 2004, 23, 756-764.	1.1	362
308	IFN-Inducible Protein 10/CXC Chemokine Ligand 10-Independent Induction of Experimental Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2004, 172, 550-559.	0.4	122
309	Regulation of Cellular and Molecular Trafficking across Human Brain Endothelial Cells by Th1- and Th2-Polarized Lymphocytes. <i>Journal of Neuropathology and Experimental Neurology</i> , 2004, 63, 223-232.	0.9	35
310	Expression of Chemokine Receptors CCR1 and CCR5 Reflects Differential Activation of Mononuclear Phagocytes in Pattern II and Pattern III Multiple Sclerosis Lesions. <i>Journal of Neuropathology and Experimental Neurology</i> , 2004, 63, 262-273.	0.9	66

#	ARTICLE	IF	CITATIONS
311	Association of CCR5 $\Delta$ 32 deletion with early death in multiple sclerosis. <i>Genetics in Medicine</i> , 2004, 6, 126-131.	1.1	53
312	Chemokines and Central Nervous System Physiology. <i>Current Topics in Membranes</i> , 2005, 55, 159-187.	0.5	1
313	CXCR3 Antagonists. <i>Annual Reports in Medicinal Chemistry</i> , 2005, , 215-225.	0.5	15
314	Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 379-390.	1.4	7
315	The Chemokine System in Experimental Autoimmune Encephalomyelitis. , 2005, , 363-377.		0
316	Chemokine-induced recruitment of genetically modified bone marrow cells into the CNS of GM1-gangliosidosis mice corrects neuronal pathology. <i>Blood</i> , 2005, 106, 2259-2268.	0.6	77
317	IFN- $\gamma$ -inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. <i>Microbes and Infection</i> , 2005, 7, 1-8.	1.0	224
318	The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease. <i>European Journal of Neurology</i> , 2005, 12, 49-54.	1.7	90
319	The chemokine CCL2 modulates Ca <sup>2+</sup> dynamics and electrophysiological properties of cultured cerebellar Purkinje neurons. <i>European Journal of Neuroscience</i> , 2005, 21, 2949-2957.	1.2	49
320	Chemokines: Integrators of Pain and Inflammation. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 834-844.	21.5	238
321	Anti-Interferon-inducible Chemokine, CXCL10, Reduces Colitis by Impairing T Helper-1 Induction and Recruitment in Mice. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 799-805.	0.9	81
322	Neural stem cells in inflammatory CNS diseases: mechanisms and therapy. <i>Journal of Cellular and Molecular Medicine</i> , 2005, 9, 303-319.	1.6	31
323	The clinical potential of chemokine receptor antagonists. , 2005, 107, 44-58.		107
324	Chemokine profile in the cerebrospinal fluid and serum of Vogt-Koyanagi-Harada disease. <i>Journal of Neuroimmunology</i> , 2005, 158, 240-244.	1.1	19
325	CSF-chemokines in HTLV-I-associated myelopathy: CXCL10 up-regulation and therapeutic effect of interferon- $\gamma$ . <i>Journal of Neuroimmunology</i> , 2005, 159, 177-182.	1.1	33
326	Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: Implications for multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005, 161, 113-122.	1.1	158
327	CCL2 and CCL5 mediate leukocyte adhesion in experimental autoimmune encephalomyelitis—an intravital microscopy study. <i>Journal of Neuroimmunology</i> , 2005, 162, 122-129.	1.1	122
328	Systemic T-cell activation in acute clinically isolated optic neuritis. <i>Journal of Neuroimmunology</i> , 2005, 162, 165-172.	1.1	23

#	ARTICLE	IF	CITATIONS
329	Increased expression of CXCR3 and CCR5 on memory CD4+ T-cells migrating into the cerebrospinal fluid of patients with neuroborreliosis: The role of CXCL10 and CXCL11. <i>Journal of Neuroimmunology</i> , 2005, 163, 128-134.	1.1	34
330	CCR5 $\Delta$ 32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005, 169, 137-143.	1.1	35
331	Characterization of relapsing autoimmune encephalomyelitis and its treatment with decoy chemokine receptor genes. <i>Journal of Neuroimmunology</i> , 2005, 170, 49-61.	1.1	17
332	CXCR3 is required for migration to dermal inflammation by normal and in vivo activated T $\alpha$ cells: differential requirements by CD4 and CD8 memory subsets. <i>European Journal of Immunology</i> , 2005, 35, 1702-1711.	1.6	49
333	Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. <i>Arthritis and Rheumatism</i> , 2005, 52, 627-636.	6.7	85
334	RON-regulated innate immunity is protective in an animal model of multiple sclerosis. <i>Annals of Neurology</i> , 2005, 57, 883-895.	2.8	38
335	Cyclopentenone prostaglandins PGA2 and 15-deoxy- $\Delta$ 12,14 PGJ2 suppress activation of murine microglia and astrocytes: Implications for multiple sclerosis. <i>Journal of Neuroscience Research</i> , 2005, 80, 66-74.	1.3	49
336	Agonists for the peroxisome proliferator-activated receptor- $\alpha$ and the retinoid X receptor inhibit inflammatory responses of microglia. <i>Journal of Neuroscience Research</i> , 2005, 81, 403-411.	1.3	126
337	$\gamma$ -chemokine receptor expression in idiopathic inflammatory myopathies. <i>Muscle and Nerve</i> , 2005, 31, 621-627.	1.0	28
338	The production of CXCR3-agonistic chemokines by synovial fibroblasts from patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2005, 25, 361-367.	1.5	49
339	Differences in systemic and central nervous system cellular immunity relevant to relapsing and remitting multiple sclerosis. <i>Journal of Neurology</i> , 2005, 252, 908-915.	1.8	25
340	Clinical implications of neuropathological findings in multiple sclerosis. <i>Journal of Neurology</i> , 2005, 252, iii10-iii14.	1.8	23
341	Butyrate blocks interferon- $\beta$ -inducible protein-10 release in human intestinal subepithelial myofibroblasts. <i>Journal of Gastroenterology</i> , 2005, 40, 483-489.	2.3	33
342	Correlations between IL-4, IL-12 levels and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients. <i>Journal of Neural Transmission</i> , 2005, 112, 797-803.	1.4	27
343	Intracellular Signal Cascade in CD4+T-Lymphocyte Migration Stimulated by Interferon- $\beta$ -Inducible Protein-10. <i>Biochemistry (Moscow)</i> , 2005, 70, 652-656.	0.7	6
344	Chemokine Signaling: The Functional Importance of Stabilizing Receptor Conformations. , 2005, , 153-170.		0
345	Transgenic expression of CCL2 in the central nervous system prevents experimental autoimmune encephalomyelitis. <i>Journal of Leukocyte Biology</i> , 2005, 77, 229-237.	1.5	37
346	Opposing Effects of CXCR3 and CCR5 Deficiency on CD8+ T Cell-Mediated Inflammation in the Central Nervous System of Virus-Infected Mice. <i>Journal of Immunology</i> , 2005, 175, 1767-1775.	0.4	47

#	ARTICLE	IF	CITATIONS
347	Increase of interferon- $\beta$ inducible chemokine CXCL10 but not chemokine CCL2 serum levels in chronic autoimmune thyroiditis. <i>European Journal of Endocrinology</i> , 2005, 152, 171-177.	1.9	82
348	Immunologic Correlates of MS Pathologic Subtypes. <i>Multiple Sclerosis Journal</i> , 2005, 11, 101-102.	1.4	2
349	Molecular Control of Physiological and Pathological T-Cell Recruitment after Mouse Spinal Cord Injury. <i>Journal of Neuroscience</i> , 2005, 25, 6576-6583.	1.7	83
350	Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. <i>Brain</i> , 2005, 128, 988-1002.	3.7	316
351	Overexpression of IFN-Induced Protein 10 and Its Receptor CXCR3 in Myasthenia Gravis. <i>Journal of Immunology</i> , 2005, 174, 5324-5331.	0.4	76
352	$\gamma\delta$ T Cells Regulate the Extent and Duration of Inflammation in the Central Nervous System by a Fas Ligand-Dependent Mechanism. <i>Journal of Immunology</i> , 2005, 174, 4678-4687.	0.4	116
353	CD26+CD4+T cell counts and attack risk in interferon-treated multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005, 11, 641-645.	1.4	14
354	Chemokines and chemokine receptors in inflammation of the CNS. <i>Expert Review of Clinical Immunology</i> , 2005, 1, 293-301.	1.3	8
355	Viral Expression of CCL2 Is Sufficient To Induce Demyelination in RAG1 $\Delta/\Delta$ Mice Infected with a Neurotropic Coronavirus. <i>Journal of Virology</i> , 2005, 79, 7113-7120.	1.5	42
356	Monokine Induced by Interferon- $\beta$ Acts as a Neurotrophic Factor on PC12 Cells and Rat Primary Sympathetic Neurons. <i>Journal of Biological Chemistry</i> , 2005, 280, 34268-34277.	1.6	6
357	BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. <i>Journal of Experimental Medicine</i> , 2005, 201, 195-200.	4.2	441
358	The pathology of multiple sclerosis. <i>Neurologic Clinics</i> , 2005, 23, 77-105.	0.8	134
359	Immunology of multiple sclerosis. <i>Neurologic Clinics</i> , 2005, 23, 149-175.	0.8	29
360	Chemokine Receptor CXCR3: An Unexpected Enigma. <i>Current Topics in Developmental Biology</i> , 2005, 68, 149-181.	1.0	136
361	The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 11094-11099.	3.3	172
362	Overview and History of Chemokines and Their Receptors. <i>Current Topics in Membranes</i> , 2005, 55, 1-47.	0.5	1
363	Increased levels of chemokine receptor CXCR3 and chemokines IP-10 and MIG in patients with primary biliary cirrhosis and their first degree relatives. <i>Journal of Autoimmunity</i> , 2005, 25, 126-132.	3.0	97
364	Multi-faceted strategies to combat disease by interference with the chemokine system. <i>Trends in Immunology</i> , 2005, 26, 268-274.	2.9	81

#	ARTICLE	IF	CITATIONS
365	Decreased IgG production but increased MIP-1 $\beta$ expression in collagen-induced arthritis in C $\alpha$ C chemokine receptor 5-deficient mice. <i>Cytokine</i> , 2005, 31, 64-71.	1.4	11
366	Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. <i>Brain Research Reviews</i> , 2005, 48, 16-42.	9.1	455
367	Involvement of beta-chemokines in the development of inflammatory demyelination. <i>Journal of Neuroinflammation</i> , 2005, 2, 7.	3.1	69
368	IMMUNOLOGY OF MULTIPLE SCLEROSIS. <i>Annual Review of Immunology</i> , 2005, 23, 683-747.	9.5	1,982
369	CNS chemokines, cytokines, and dendritic cells in autoimmune demyelination. <i>Journal of the Neurological Sciences</i> , 2005, 228, 210-214.	0.3	32
370	B-Cell Immunity in Multiple Sclerosis. , 2005, , 113-130.		0
371	Role of Microglia and Macrophages in Eae. , 2005, , 109-131.		0
372	An investigation of polymorphisms in the 4q13.3-21.1 CXC chemokine gene cluster for association with multiple sclerosis in Australians. <i>Multiple Sclerosis Journal</i> , 2006, 12, 710-722.	1.4	5
373	Cytokines and chemokines in cerebrospinal fluid and serum of adult patients with acute disseminated encephalomyelitis. <i>Journal of the Neurological Sciences</i> , 2006, 247, 202-207.	0.3	65
374	Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. <i>Brain</i> , 2006, 129, 200-211.	3.7	485
375	Amelioration of autoimmune neuroinflammation by recombinant human alpha-fetoprotein. <i>Experimental Neurology</i> , 2006, 198, 136-144.	2.0	43
376	MS treatment: New perspectives. <i>Clinical Neurology and Neurosurgery</i> , 2006, 108, 339-345.	0.6	9
377	The Many Roles of Chemokines and Chemokine Receptors in Inflammation. <i>New England Journal of Medicine</i> , 2006, 354, 610-621.	13.9	2,207
378	Microglial cells initiate vigorous yet non-protective immune responses during HSV-1 brain infection. <i>Virus Research</i> , 2006, 121, 1-10.	1.1	88
379	Chemokine blockers â€“ therapeutics in the making?. <i>Trends in Pharmacological Sciences</i> , 2006, 27, 41-47.	4.0	171
381	Immunology and immunopathology of African trypanosomiasis. <i>Anais Da Academia Brasileira De Ciencias</i> , 2006, 78, 645-665.	0.3	88
382	Role of Th1 and Th2 Cells in Autoimmunity. , 2006, , 83-101.		1
383	Biomarkers in Multiple Sclerosis. <i>Disease Markers</i> , 2006, 22, 183-185.	0.6	25

#	ARTICLE	IF	CITATIONS
384	Role of CXCR3 carboxyl terminus and third intracellular loop in receptor-mediated migration, adhesion and internalization in response to CXCL11. <i>Blood</i> , 2006, 107, 3821-3831.	0.6	43
386	An investigation of polymorphisms in the 17q11.2-12 CC chemokine gene cluster for association with multiple sclerosis in Australians. <i>BMC Medical Genetics</i> , 2006, 7, 64.	2.1	8
387	CCR3, CCR5, CCR8 and CXCR3 expression in memory T helper cells from allergic rhinitis patients, asymptotically sensitized and healthy individuals. <i>Clinical and Molecular Allergy</i> , 2006, 4, 6.	0.8	8
388	Inflammation in the Central Nervous System: the Role for Dendritic Cells. <i>Brain Pathology</i> , 2003, 13, 23-33.	2.1	67
389	Differential Expression of the Chemokine Receptors CX <sub>3</sub> CR1 and CCR1 by Microglia and Macrophages in Myelin $\rightarrow$ Oligodendrocyte $\rightarrow$ Glycoprotein $\rightarrow$ Induced Experimental Autoimmune Encephalomyelitis. <i>Brain Pathology</i> , 2003, 13, 617-629.	2.1	37
390	Effect of high-dose methylprednisolone treatment on CCR5 expression on blood cells in MS exacerbation. <i>Acta Neurologica Scandinavica</i> , 2006, 113, 163-166.	1.0	16
391	Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors. <i>Immunological Reviews</i> , 2006, 213, 195-212.	2.8	77
392	Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. <i>Clinical and Experimental Immunology</i> , 2006, 146, 330-338.	1.1	299
393	Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. <i>Clinical Endocrinology</i> , 2006, 64, 189-195.	1.2	67
394	Serum and cerebral spinal fluid levels of chemokines and Th2 cytokines in <i>Schistosoma mansoni</i> myelradiculopathy. <i>Parasite Immunology</i> , 2006, 28, 473-478.	0.7	28
395	Dynamic T-lymphocyte Chemokine Receptor Expression Induced by Interferon-beta Therapy in Multiple Sclerosis. <i>Scandinavian Journal of Immunology</i> , 2006, 64, 155-163.	1.3	26
396	The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density. <i>Immunology</i> , 2006, 119, 551-561.	2.0	29
397	MCP-1 in the cerebrospinal fluid of children with acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2006, 30, 1259-1261.	0.4	21
398	Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. <i>Acta Neuropathologica</i> , 2006, 112, 195-204.	3.9	207
399	Soluble CD26 and CD30 levels in CSF and sera of patients with relapsing neuromyelitis optica. <i>Journal of Neurology</i> , 2006, 253, 111-113.	1.8	8
400	CCR5 expression on monocytes and T cells: Modulation by transmigration across the blood $\rightarrow$ brain barrier in vitro. <i>Cellular Immunology</i> , 2006, 243, 19-29.	1.4	47
401	IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: Implications for their possible immunopathogenic roles. <i>Journal of Neuroimmunology</i> , 2006, 175, 176-182.	1.1	50
402	Peroxisome proliferator-activated receptor- $\gamma$ and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. <i>Journal of Neuroimmunology</i> , 2006, 176, 95-105.	1.1	88



#	ARTICLE	IF	CITATIONS
403	Deficient Fas expression by CD4+ CCR5+ T cells in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2006, 180, 147-158.	1.1	15
404	CD4+ memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2006, 181, 157-164.	1.1	51
405	Mechanisms of the adaptive immune response inside the central nervous system during inflammatory and autoimmune diseases. , 2006, 111, 555-566.		30
406	Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFN $\gamma$ -responsive genes in peripheral blood lymphocytes in vitro: an implication for IFN $\gamma$ -related adverse effects in multiple sclerosis. <i>BMC Neurology</i> , 2006, 6, 18.	0.8	52
407	Antagonist of interferon-inducible protein 10/CXCL10 ameliorates the progression of autoimmune sialadenitis in MRL/lpr mice. <i>Arthritis and Rheumatism</i> , 2006, 54, 1174-1183.	6.7	55
408	Overexpression of phosphorylated STAT-1 $\gamma$ in the labial salivary glands of patients with Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2006, 54, 3476-3484.	6.7	38
409	Challenge with innate and protein antigens induces CCR7 expression by microglia in vitro and in vivo. <i>Glia</i> , 2006, 54, 861-872.	2.5	42
410	Childhood multiple sclerosis: A review. <i>Mental Retardation and Developmental Disabilities Research Reviews</i> , 2006, 12, 147-156.	3.5	12
411	Neutralization of the chemokine CXCL10 reduces apoptosis and increases axon sprouting after spinal cord injury. <i>Journal of Neuroscience Research</i> , 2006, 84, 724-734.	1.3	94
412	B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulation. <i>Annals of Neurology</i> , 2006, 59, 880-892.	2.8	283
413	Longitudinal analysis of immune cell phenotypes in early stage multiple sclerosis: distinctive patterns characterize MRI-active patients. <i>Brain</i> , 2006, 129, 1993-2007.	3.7	39
414	Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. <i>Brain</i> , 2006, 129, 212-223.	3.7	188
415	Interferon- $\gamma$ -Inducible Chemokine CXCL10 Involvement in Graves' Ophthalmopathy: Modulation by Peroxisome Proliferator-Activated Receptor- $\gamma$ Agonists. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 614-620.	1.8	144
416	Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis. <i>Brain</i> , 2006, 129, 2635-2647.	3.7	75
417	Oligomerization of CXCL10 Is Necessary for Endothelial Cell Presentation and In Vivo Activity. <i>Journal of Immunology</i> , 2006, 177, 6991-6998.	0.4	95
418	Role of IP-10/CXCL10 in the progression of pancreatitis-like injury in mice after murine retroviral infection. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 291, G345-G354.	1.6	19
419	Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for immune-related molecules by central nervous system mixed glial cell cultures. <i>Multiple Sclerosis Journal</i> , 2006, 12, 149-168.	1.4	30
420	WSX-1 plays a significant role for the initiation of experimental autoimmune uveitis. <i>International Immunology</i> , 2006, 19, 93-98.	1.8	21



#	ARTICLE	IF	CITATIONS
421	Periplocoside E Inhibits Experimental Allergic Encephalomyelitis by Suppressing Interleukin 12-Dependent CCR5 Expression and Interferon- $\beta$ -Dependent CXCR3 Expression in T Lymphocytes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 1153-1162.	1.3	24
422	The CC Chemokine Receptor 5 Is Important in Control of Parasite Replication and Acute Cardiac Inflammation following Infection with <i>Trypanosoma cruzi</i> . <i>Infection and Immunity</i> , 2006, 74, 135-143.	1.0	72
423	Variations in chemokine receptor and cytokine expression during pregnancy in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2006, 12, 421-427.	1.4	32
424	CXCR3 Requires Tyrosine Sulfation for Ligand Binding and a Second Extracellular Loop Arginine Residue for Ligand-Induced Chemotaxis. <i>Molecular and Cellular Biology</i> , 2006, 26, 5838-5849.	1.1	117
425	CXCL10 Is the Key Ligand for CXCR3 on CD8+ Effector T Cells Involved in Immune Surveillance of the Lymphocytic Choriomeningitis Virus-Infected Central Nervous System. <i>Journal of Immunology</i> , 2006, 176, 4235-4243.	0.4	129
426	Severe Disease, Unaltered Leukocyte Migration, and Reduced IFN- $\beta$ Production in CXCR3 $^{-/-}$ Mice with Experimental Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2006, 176, 4399-4409.	0.4	142
427	Expression of the chemokine receptor CCR1 in human renal allografts. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 1720-1729.	0.4	19
428	CCR7 expression on peripheral blood lymphocytes is up-regulated following treatment of multiple sclerosis with interferon-beta. <i>Neurological Research</i> , 2007, 29, 763-766.	0.6	12
429	Therapeutic neutralization of CXCL10 decreases secondary degeneration and functional deficit after spinal cord injury in mice. <i>Regenerative Medicine</i> , 2007, 2, 771-783.	0.8	42
430	Naive and Memory CD4+T-cells in the Cerebrospinal Fluid of Children with Aseptic Meningitis Following Measles-Mumps-Rubella Vaccination and Enteroviral Meningitis. <i>Immunological Investigations</i> , 2007, 36, 321-335.	1.0	2
431	CXCR3 Signaling Reduces the Severity of Experimental Autoimmune Encephalomyelitis by Controlling the Parenchymal Distribution of Effector and Regulatory T Cells in the Central Nervous System. <i>Journal of Immunology</i> , 2007, 179, 2774-2786.	0.4	181
432	NK Cells Stimulate Recruitment of CXCR3+ T Cells to the Brain during <i>Plasmodium berghei</i> -Mediated Cerebral Malaria. <i>Journal of Immunology</i> , 2007, 178, 5779-5788.	0.4	147
433	CCR5 and CXCR3 Are Dispensable for Liver Infiltration, but CCR5 Protects against Virus-Induced T-Cell-Mediated Hepatic Steatosis. <i>Journal of Virology</i> , 2007, 81, 10101-10112.	1.5	12
434	Interferon- $\beta$ Is a Potent Inducer of Interferon Regulatory Factor-1/2-Dependent IP-10/CXCL10 Expression in Primary Human Endothelial Cells. <i>Journal of Vascular Research</i> , 2007, 44, 51-60.	0.6	57
435	CXCL11 (Interferon-Inducible T-Cell Alpha Chemoattractant) and Interleukin-18 in Relapsing-Remitting Multiple Sclerosis Patients Treated with Methylprednisolone. <i>European Neurology</i> , 2007, 58, 228-232.	0.6	12
436	Molecular targets for disrupting leukocyte trafficking during multiple sclerosis. <i>Expert Reviews in Molecular Medicine</i> , 2007, 9, 1-19.	1.6	14
439	Inhibition of glial cell activation ameliorates the severity of experimental autoimmune encephalomyelitis. <i>Neuroscience Research</i> , 2007, 59, 457-466.	1.0	56
440	Antagonists of CXCR3: a review of current progress. , 2007, , 79-88.		6

#	ARTICLE	IF	CITATIONS
441	Relationship of immunologic abnormalities and disease stage in multiple sclerosis: Implications for therapy. <i>Journal of the Neurological Sciences</i> , 2007, 259, 90-94.	0.3	10
442	Cerebrospinal Fluid Analysis in Multiple Sclerosis. <i>International Review of Neurobiology</i> , 2007, 79, 341-356.	0.9	30
443	The blood-brain-barrier in multiple sclerosis: Functional roles and therapeutic targeting. <i>Autoimmunity</i> , 2007, 40, 148-160.	1.2	95
444	Expression of Interferon-Gamma-Inducible Protein-10 and Its Receptor CXCR3 in Chronic Pancreatitis. <i>Pancreatology</i> , 2007, 7, 479-490.	0.5	15
445	CXCL10/IP-10: A missing link between inflammation and anti-angiogenesis in preeclampsia?. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2007, 20, 777-792.	0.7	112
446	Role of Chemokines in Endocrine Autoimmune Diseases. <i>Endocrine Reviews</i> , 2007, 28, 492-520.	8.9	224
447	Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE. <i>Journal of Neuroinflammation</i> , 2007, 4, 14.	3.1	70
448	Concise Review: Mesenchymal Stem Cells: Their Phenotype, Differentiation Capacity, Immunological Features, and Potential for Homing. <i>Stem Cells</i> , 2007, 25, 2739-2749.	1.4	2,109
449	Increased Intrathecal Chemokine Receptor CCR2 Expression in Multiple Sclerosis. <i>Biomarker Insights</i> , 2007, 2, 117727190700200.	1.0	9
450	Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients. <i>Annals of Neurology</i> , 2007, 62, 34-39.	2.8	46
451	Current concepts of the cellular and molecular pathophysiology of multiple sclerosis. <i>Developmental Neurobiology</i> , 2007, 67, 1248-1265.	1.5	34
452	The target tissue in autoimmunity - an influential niche. <i>European Journal of Immunology</i> , 2007, 37, 589-597.	1.6	24
453	Induction of the genes for <i>Cxcl9</i> and <i>Cxcl10</i> is dependent on IFN- $\gamma$ but shows differential cellular expression in experimental autoimmune encephalomyelitis and by astrocytes and microglia <i>in vitro</i> . <i>Glia</i> , 2007, 55, 1728-1739.	2.5	113
454	Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 3339-3343.	1.0	88
455	Chemokines and Chemokine Receptors in Neurological Disease: Raise, Retain, or Reduce?. <i>Neurotherapeutics</i> , 2007, 4, 590-601.	2.1	157
456	Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-4330, using a murine CXCR3 internalization assay. <i>British Journal of Pharmacology</i> , 2007, 152, 1260-1271.	2.7	17
457	Expression of Chemokine Receptors CCR7 and CCR8 in the CNS During ChREAE. <i>Scandinavian Journal of Immunology</i> , 2007, 66, 383-392.	1.3	19
458	CCR7, CCR8, CCR9 and CCR10 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced status epilepticus. <i>Journal of Neurochemistry</i> , 2007, 100, 1072-1088.	2.1	40

#	ARTICLE	IF	CITATIONS
459	Dexamethasone suppresses monocyte chemoattractant protein-1 production via mitogen activated protein kinase phosphatase-1 dependent inhibition of Jun N-terminal kinase and p38 mitogen-activated protein kinase in activated rat microglia. <i>Journal of Neurochemistry</i> , 2007, 102, 667-678.	2.1	112
460	CXCL10 haplotypes and multiple sclerosis: association and correlation with clinical course. <i>European Journal of Neurology</i> , 2007, 14, 162-167.	1.7	19
461	Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. <i>Acta Neurologica Scandinavica</i> , 2007, 115, 137-146.	1.0	193
462	Chemokine receptor CCR5 in interferon-treated multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2007, 115, 413-418.	1.0	14
463	Interleukin 10 and TNF $\alpha$ synergistically enhance the expression of the G protein-coupled formylpeptide receptor 2 in microglia. <i>Neurobiology of Disease</i> , 2007, 27, 90-98.	2.1	10
464	Increase of CD8+ T-effector memory cells in peripheral blood of patients with relapsing&#x2013;remitting multiple sclerosis compared to healthy controls. <i>Journal of Neuroimmunology</i> , 2007, 183, 168-174.	1.1	36
465	CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2007, 190, 157-164.	1.1	53
466	DNA Microarray in Search of New Drug Targets for Myasthenia Gravis. <i>Annals of the New York Academy of Sciences</i> , 2007, 1107, 111-117.	1.8	6
467	The production of interferon- $\gamma$ -inducible protein 10 by granulocytes and monocytes is associated with ulcerative colitis disease activity. <i>Journal of Gastroenterology</i> , 2007, 42, 947-956.	2.3	24
468	Multiple sclerosis therapy: An update on recently finished trials. <i>Journal of Neurology</i> , 2007, 254, 1473-1490.	1.8	11
469	Astrocytes in multiple sclerosis: A product of their environment. <i>Cellular and Molecular Life Sciences</i> , 2008, 65, 2702-20.	2.4	279
470	Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. <i>Journal of Neurochemistry</i> , 2008, 77, 132-145.	2.1	16
471	Towards Small&#x2013;Molecule CXCR3 Ligands with Clinical Potential. <i>ChemMedChem</i> , 2008, 3, 861-872.	1.6	75
472	Reciprocal cross-talk between RANKL and interferon- $\gamma$ -inducible protein 10 is responsible for bone-erosive experimental arthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 1332-1342.	6.7	105
473	Design and optimization of imidazole derivatives as potent CXCR3 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 608-613.	1.0	32
474	Discovery of small molecule benzimidazole antagonists of the chemokine receptor CXCR3. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1573-1576.	1.0	40
475	Lead identification of 2-iminobenzimidazole antagonists of the chemokine receptor CXCR3. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2414-2419.	1.0	15
476	Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 688-693.	1.0	43

#	ARTICLE	IF	CITATIONS
477	Cytokines and Chemokines. , 2008, , 183-205.		1
478	The effects of methylprednisolone and mitoxantrone on CCL5-induced migration of lymphocytes in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2008, 118, 120-125.	1.0	18
479	SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients. <i>Laboratory Investigation</i> , 2008, 88, 243-255.	1.7	58
480	Novel therapeutic strategies for multiple sclerosis â€” a multifaceted adversary. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 909-925.	21.5	147
481	Antagonism of the Chemokine Receptors CXCR3 and CXCR4 Reduces the Pathology of Experimental Autoimmune Encephalomyelitis. <i>Brain Pathology</i> , 2008, 18, 080415182616831-???	2.1	77
482	Expression of CXCL4 in microglia <i>in vitro</i> and <i>in vivo</i> and its possible signaling through CXCR3. <i>Journal of Neurochemistry</i> , 2008, 105, 1726-1736.	2.1	70
483	Pro-inflammatory functions of astrocytes correlate with viral clearance and strain-dependent protection from TMEV-induced demyelinating disease. <i>Virology</i> , 2008, 375, 24-36.	1.1	26
484	Elevated level of the proinflammatory chemokine, RANTES/CCL5, in the periaqueductal grey causes hyperalgesia in rats. <i>European Journal of Pharmacology</i> , 2008, 592, 93-95.	1.7	36
485	Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2008, 195, 140-145.	1.1	54
486	Chronic CXCL10 alters the level of activated ERK1/2 and transcriptional factors CREB and NF-Î²B in hippocampal neuronal cell culture. <i>Journal of Neuroimmunology</i> , 2008, 195, 36-46.	1.1	17
487	The use of chemokine antagonists in EAE models. <i>Journal of Neuroimmunology</i> , 2008, 198, 27-30.	1.1	31
488	Chemokine signaling and integrin activation in lymphocyte migration into the inflamed brain. <i>Journal of Neuroimmunology</i> , 2008, 198, 20-26.	1.1	34
489	Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implication for assessment of disease activity and treatment. <i>Journal of Neuroimmunology</i> , 2008, 199, 142-150.	1.1	71
490	Development of a novel chemokine-mediated <i>in vivo</i> T cell recruitment assay. <i>Journal of Immunological Methods</i> , 2008, 331, 127-139.	0.6	42
491	Multiple Sclerosis and Other Demyelinating Diseases. , 2008, , 239-255.		1
492	Gender-specific influence of the chromosome 16 chemokine gene cluster on the susceptibility to Multiple Sclerosis. <i>Journal of the Neurological Sciences</i> , 2008, 267, 86-90.	0.3	30
493	Therapeutic targeting of chemokine signaling in Multiple Sclerosis. <i>Journal of the Neurological Sciences</i> , 2008, 274, 31-38.	0.3	44
494	Kinin B2receptor regulates chemokines CCL2 and CCL5 expression and modulates leukocyte recruitment and pathology in experimental autoimmune encephalomyelitis (EAE) in mice. <i>Journal of Neuroinflammation</i> , 2008, 5, 49.	3.1	45

#	ARTICLE	IF	CITATIONS
495	Macrophages, Microglia, and Dendritic C. , 2008, , 89-104.		1
496	Neural precursor cells inhibit multiple inflammatory signals. <i>Molecular and Cellular Neurosciences</i> , 2008, 39, 335-341.	1.0	68
497	Genistein down-modulates pro-inflammatory cytokines and reverses clinical signs of experimental autoimmune encephalomyelitis. <i>International Immunopharmacology</i> , 2008, 8, 1291-1297.	1.7	55
498	Glucocorticoids regulate innate immunity in a model of multiple sclerosis: reciprocal interactions between the A1 adenosine receptor and $\beta$ -arrestin1 in monocytoïd cells. <i>FASEB Journal</i> , 2008, 22, 786-796.	0.2	45
499	Distinct Cellular Patterns of Upregulated Chemokine Expression Supporting a Prominent Inflammatory Role in Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2008, 25, 959-974.	1.7	146
500	Production of CCL2 by Central Nervous System Cells Regulates Development of Murine Experimental Autoimmune Encephalomyelitis through the Recruitment of TNF- and iNOS-Expressing Macrophages and Myeloid Dendritic Cells. <i>Journal of Immunology</i> , 2008, 180, 7376-7384.	0.4	82
501	MDC/CCL22 intrathecal levels in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 547-549.	1.4	28
502	Matrix Metalloproteinase Processing of CXCL11/I-TAC Results in Loss of Chemoattractant Activity and Altered Glycosaminoglycan Binding. <i>Journal of Biological Chemistry</i> , 2008, 283, 19389-19399.	1.6	88
503	CCR5 Deficiency Aggravates Crescentic Glomerulonephritis in Mice. <i>Journal of Immunology</i> , 2008, 181, 6546-6556.	0.4	55
504	A Complex Interplay among Virus, Dendritic Cells, T Cells, and Cytokines in Dengue Virus Infections. <i>Journal of Immunology</i> , 2008, 181, 5865-5874.	0.4	70
505	RANTES Modulates the Release of Glutamate in Human Neocortex. <i>Journal of Neuroscience</i> , 2008, 28, 12231-12240.	1.7	57
506	Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury. <i>Multiple Sclerosis Journal</i> , 2008, 14, 1036-1043.	1.4	15
507	Human Brain Microvascular Endothelial Cells and Umbilical Vein Endothelial Cells Differentially Facilitate Leukocyte Recruitment and Utilize Chemokines for T Cell Migration. <i>Clinical and Developmental Immunology</i> , 2008, 2008, 1-8.	3.3	85
508	CXCL10 ( $\hat{A}$ ) and CCL2 ( ) chemokines in systemic sclerosis a longitudinal study. <i>Rheumatology</i> , 2008, 47, 45-49.	0.9	109
509	The Chemokine Receptor CXCR3 Is Degraded following Internalization and Is Replenished at the Cell Surface by De Novo Synthesis of Receptor. <i>Journal of Immunology</i> , 2008, 180, 6713-6724.	0.4	120
510	Noncompetitive Antagonism and Inverse Agonism as Mechanism of Action of Nonpeptidergic Antagonists at Primate and Rodent CXCR3 Chemokine Receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 325, 544-555.	1.3	57
511	CCR5 expression on macrophages/microglia is associated with early remyelination in multiple sclerosis lesions. <i>Multiple Sclerosis Journal</i> , 2008, 14, 728-733.	1.4	30
512	EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN- $\hat{P}$ and IL-2. <i>Journal of Experimental Medicine</i> , 2008, 205, 1763-1773.	4.2	244

#	ARTICLE	IF	CITATIONS
513	Anti-Selectin Therapy for the Treatment of Inflammatory Diseases. <i>Inflammation and Allergy: Drug Targets</i> , 2008, 7, 85-93.	1.8	54
514	CC chemokine receptor 5 gene promoter activation by the cyclic AMP response element binding transcription factor. <i>Blood</i> , 2008, 112, 1610-1619.	0.6	25
515	Plasmacytoid Dendritic Cells in Multiple Sclerosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 388-401.	0.9	110
516	10 Most Commonly Asked Questions About Cerebrospinal Fluid Characteristics in Demyelinating Disorders of the Central Nervous System. <i>Neurologist</i> , 2008, 14, 60-65.	0.4	6
517	Cytokines and Myelination in the Central Nervous System. <i>Scientific World Journal, The</i> , 2008, 8, 1119-1147.	0.8	114
518	Lymphocytic Choriomeningitis Virus-Induced Central Nervous System Disease: a Model for Studying the Role of Chemokines in Regulating the Acute Antiviral CD8 <sup>+</sup> T-Cell Response in an Immune-Privileged Organ. <i>Journal of Virology</i> , 2009, 83, 20-28.	1.5	24
519	Ig-Like Transcript 3 Regulates Expression of Proinflammatory Cytokines and Migration of Activated T Cells. <i>Journal of Immunology</i> , 2009, 182, 5208-5216.	0.4	46
520	Fulminant Lymphocytic Choriomeningitis Virus-Induced Inflammation of the CNS Involves a Cytokine-Chemokine-Cytokine-Chemokine Cascade. <i>Journal of Immunology</i> , 2009, 182, 1079-1087.	0.4	37
521	Immunopathogenesis of multiple sclerosis. <i>Annals of Indian Academy of Neurology</i> , 2009, 12, 215.	0.2	17
522	Enhancement of Chemokine Expression by Interferon Beta Therapy in Patients With Multiple Sclerosis. <i>Archives of Neurology</i> , 2009, 66, 1216.	4.9	37
523	Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. <i>Neurology</i> , 2009, 72, 1922-1930.	1.5	131
524	Suppression of experimental autoimmune myasthenia gravis by inhibiting the signaling between IFN- $\gamma$ inducible protein 10 (IP-10) and its receptor CXCR3. <i>Journal of Neuroimmunology</i> , 2009, 209, 87-95.	1.1	19
525	Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke. <i>BMC Neuroscience</i> , 2009, 10, 126.	0.8	128
526	CXCL10 and autoimmune diseases. <i>Autoimmunity Reviews</i> , 2009, 8, 379-383.	2.5	265
527	Differential susceptibility to apoptosis of CD4 <sup>+</sup> T cells expressing CCR5 and CXCR3 in patients with MS. <i>Clinical Immunology</i> , 2009, 133, 364-374.	1.4	16
528	Specific central nervous system recruitment of HLA-DR <sup>+</sup> regulatory T cells in multiple sclerosis. <i>Annals of Neurology</i> , 2009, 66, 171-183.	2.8	67
529	CCR6 regulates EAE pathogenesis by controlling regulatory CD4 <sup>+</sup> T cell recruitment to target tissues. <i>European Journal of Immunology</i> , 2009, 39, 1671-1681.	1.6	114
530	Mechanisms Underlying the Process of Demyelination in Multiple Sclerosis. <i>Neurophysiology</i> , 2009, 41, 365-373.	0.2	4



#	ARTICLE	IF	CITATIONS
531	CCR5-Delta32 Allele is Associated with the Risk of Developing Multiple Sclerosis in the Iranian Population. <i>Cellular and Molecular Neurobiology</i> , 2009, 29, 1205-1209.	1.7	23
532	The CCR5 (Δ2135C/T) Polymorphism may be Associated with the Development of Kawasaki Disease in Korean Children. <i>Journal of Clinical Immunology</i> , 2009, 29, 22-28.	2.0	17
533	Cerebral cortical gene expression in acutely anemic rats: a microarray analysis. <i>Canadian Journal of Anaesthesia</i> , 2009, 56, 921-934.	0.7	3
534	Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype. <i>Laboratory Investigation</i> , 2009, 89, 742-759.	1.7	74
535	Sulfated tyrosines 27 and 29 in the N-terminus of human CXCR3 participate in binding native IP-10. <i>Acta Pharmacologica Sinica</i> , 2009, 30, 193-201.	2.8	20
536	The Chemokine CCL5 Is Essential for Leukocyte Recruitment in a Model of Severe Herpes simplex Encephalitis. <i>Annals of the New York Academy of Sciences</i> , 2009, 1153, 256-263.	1.8	46
537	Imidazo-pyrazine derivatives as potent CXCR3 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 5200-5204.	1.0	38
538	Optimization of a series of quinazolinone-derived antagonists of CXCR3. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 5114-5118.	1.0	33
539	Mechanisms and implications of adaptive immune responses after traumatic spinal cord injury. <i>Neuroscience</i> , 2009, 158, 1112-1121.	1.1	158
540	Role of chemokines in the enhancement of BBB permeability and inflammatory infiltration after rabies virus infection. <i>Virus Research</i> , 2009, 144, 18-26.	1.1	81
541	CXCL10 and CCL2 serum levels in patients with mixed cryoglobulinaemia and hepatitis C. <i>Digestive and Liver Disease</i> , 2009, 41, 42-48.	0.4	22
542	Induction of the CXC Chemokine Interferon-γ-Inducible Protein 10 Regulates the Reparative Response Following Myocardial Infarction. <i>Circulation Research</i> , 2009, 105, 973-983.	2.0	113
543	Kv1.3 potassium channels as a therapeutic target in multiple sclerosis. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 909-924.	1.5	79
544	T-Cells in Multiple Sclerosis. <i>Results and Problems in Cell Differentiation</i> , 2009, , 75-98.	0.2	28
545	Biomarkers in Multiple Sclerosis. <i>Blue Books of Neurology</i> , 2010, , 120-146.	0.1	0
546	Anti-chemokine small molecule drugs: a promising future?. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 345-355.	1.9	94
547	Transgenic mouse models of multiple sclerosis. <i>Cellular and Molecular Life Sciences</i> , 2010, 67, 4011-4034.	2.4	18
548	Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge. <i>Journal of Neuroimmunology</i> , 2010, 220, 34-42.	1.1	57

#	ARTICLE	IF	CITATIONS
549	Myelin ingestion by macrophages promotes their motility and capacity to recruit myeloid cells. <i>Journal of Neuroimmunology</i> , 2010, 225, 112-117.	1.1	11
550	The emerging role for chemokines in epilepsy. <i>Journal of Neuroimmunology</i> , 2010, 224, 22-27.	1.1	137
551	Plasmacytoid dendritic cells in multiple sclerosis: Chemokine and chemokine receptor modulation by interferon-beta. <i>Journal of Neuroimmunology</i> , 2010, 226, 158-164.	1.1	33
552	Expression of chemokine receptors on peripheral blood lymphocytes in multiple sclerosis and neuromyelitis optica. <i>BMC Neurology</i> , 2010, 10, 113.	0.8	30
553	Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: Tâ€cell infiltration and positioning of malignant B cells. <i>International Journal of Cancer</i> , 2010, 127, 2300-2312.	2.3	86
554	CXCR3 blockade inhibits Tâ€cell migration into the CNS during EAE and prevents development of adoptively transferred, but not actively induced, disease. <i>European Journal of Immunology</i> , 2010, 40, 2751-2761.	1.6	68
555	Discovery of a novel series of CXCR3 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 3614-3617.	1.0	18
556	Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity - a tale of conflict and conundrum. <i>Neuropathology and Applied Neurobiology</i> , 2010, 36, 368-387.	1.8	228
557	Genetic variants of CC chemokine genes in experimental autoimmune encephalomyelitis, multiple sclerosis and rheumatoid arthritis. <i>Genes and Immunity</i> , 2010, 11, 142-154.	2.2	23
558	Platelet Chemokines and Chemokine Receptors: Linking Hemostasis, Inflammation, and Host Defense. <i>Microcirculation</i> , 2010, 10, 335-350.	1.0	172
559	Appearance of CXCL10-expressing cell clusters is common for traumatic brain injury and neurodegenerative disorders. <i>European Journal of Neuroscience</i> , 2010, 31, 852-863.	1.2	36
560	Lessons from the Past and Future Approaches for Immunologic Therapies in Multiple Sclerosis. <i>Blue Books of Neurology</i> , 2010, , 388-426.	0.1	0
561	The multiple faces of CXCL12 (SDF-1 $\alpha$ ) in the regulation of immunity during health and disease. <i>Journal of Leukocyte Biology</i> , 2010, 88, 463-473.	1.5	187
562	CCR1 Antagonists: What Have We Learned From Clinical Trials. <i>Current Topics in Medicinal Chemistry</i> , 2010, 10, 1268-1277.	1.0	89
563	Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. <i>Multiple Sclerosis Journal</i> , 2010, 16, 208-217.	1.4	139
564	TNFR1 plays a critical role in the control of severe HSV-1 encephalitis. <i>Neuroscience Letters</i> , 2010, 479, 58-62.	1.0	22
565	Th1 (CXCL10) and Th2 (CCL2) chemokine expression in patients with immune thrombocytopenia. <i>Human Immunology</i> , 2010, 71, 586-591.	1.2	30
566	Therapeutic Approaches to Multiple Sclerosis. <i>BioDrugs</i> , 2010, 24, 249-274.	2.2	22



#	ARTICLE	IF	CITATIONS
567	Evaluation of Serum Levels of Chemokines during Interferon- $\beta$ Treatment in Multiple Sclerosis Patients. <i>CNS Drugs</i> , 2011, 25, 971-981.	2.7	14
568	Genetics for understanding and predicting clinical progression in multiple sclerosis. <i>Revue Neurologique</i> , 2011, 167, 791-801.	0.6	3
569	Potential role and mechanism of IFN-gamma inducible protein-10 on receptor activator of nuclear factor kappa-B ligand (RANKL) expression in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2011, 13, R104.	1.6	34
570	Angiotensin II Type 1 receptor (AT1) signaling in astrocytes regulates synaptic degeneration-induced leukocyte entry to the central nervous system. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 897-904.	2.0	48
571	Interactions between chemokine and mu-opioid receptors: Anatomical findings and electrophysiological studies in the rat periaqueductal grey. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 360-372.	2.0	59
572	Altered hippocampal synaptic transmission in transgenic mice with astrocyte-targeted enhanced CCL2 expression. <i>Brain, Behavior, and Immunity</i> , 2011, 25, S106-S119.	2.0	39
573	The chemokine receptor CCR5 in the central nervous system. <i>Progress in Neurobiology</i> , 2011, 93, 297-311.	2.8	86
574	Biomarker-based dissection of neurodegenerative diseases. <i>Progress in Neurobiology</i> , 2011, 95, 520-534.	2.8	82
575	Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis. <i>Neurology Research International</i> , 2011, 2011, 1-6.	0.5	23
576	Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes. <i>Immunology</i> , 2011, 132, 503-515.	2.0	75
577	CXCR3 ligands: redundant, collaborative and antagonistic functions. <i>Immunology and Cell Biology</i> , 2011, 89, 207-215.	1.0	766
578	CXCR3 in T cell function. <i>Experimental Cell Research</i> , 2011, 317, 620-631.	1.2	763
579	Chemokines as targets for therapy. <i>Experimental Cell Research</i> , 2011, 317, 602-612.	1.2	41
580	Suppression of human CD4+ T cell activation by 3,4-dimethoxycinnamonyl-anthranilic acid (tranilast) is mediated by CXCL9 and CXCL10. <i>Biochemical Pharmacology</i> , 2011, 82, 632-641.	2.0	41
581	CCL5 induces a pro-inflammatory profile in microglia in vitro. <i>Cellular Immunology</i> , 2011, 270, 164-171.	1.4	92
582	A broad upregulation of cerebral chemokine genes by peripherally-generated inflammatory mediators. <i>Metabolic Brain Disease</i> , 2011, 26, 49-59.	1.4	25
583	CXCL10/CXCR3 signaling in glia cells differentially affects NMDA-induced cell death in CA and DG neurons of the mouse hippocampus. <i>Hippocampus</i> , 2011, 21, 220-232.	0.9	49
584	Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. <i>Cancer</i> , 2011, 117, 1163-1171.	2.0	116

#	ARTICLE	IF	CITATIONS
585	CCL5, CXCL10 and CXCL11 Chemokines in Patients with Active and Stable Relapsing-Remitting Multiple Sclerosis. <i>NeuroImmunoModulation</i> , 2011, 18, 67-72.	0.9	30
586	Racial Differences in Chronic Immune Stimulatory Conditions and Risk of Non-Hodgkin's Lymphoma in Veterans From the United States. <i>Journal of Clinical Oncology</i> , 2011, 29, 378-385.	0.8	45
587	Vascular inflammation in central nervous system diseases: adhesion receptors controlling leukocyte-endothelial interactions. <i>Journal of Leukocyte Biology</i> , 2010, 89, 539-556.	1.5	136
588	Functional Duality of Astrocytes in Myelination. <i>Journal of Neuroscience</i> , 2011, 31, 13028-13038.	1.7	112
591	Fractalkine Gene Receptor Polymorphism in Patients With Multiple Sclerosis. <i>International Journal of Neuroscience</i> , 2012, 123, 31-37.	0.8	22
592	Differential Regulation of CD4+ T Cell Adhesion to Cerebral Microvascular Endothelium by the $\beta$ 2-Chemokines CCL2 and CCL3. <i>International Journal of Molecular Sciences</i> , 2012, 13, 16119-16140.	1.8	17
593	Interferon- $\beta$ 21b Increases Th2 Response in Neuromyelitis Optica. <i>International Journal of Molecular Sciences</i> , 2012, 13, 12213-12223.	1.8	5
594	Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 4598-4603.	3.3	61
595	CCR2+CCR5+ T Cells Produce Matrix Metalloproteinase-9 and Osteopontin in the Pathogenesis of Multiple Sclerosis. <i>Journal of Immunology</i> , 2012, 189, 5057-5065.	0.4	70
596	Neuroschistosomiasis mansoni. <i>Neurologist</i> , 2012, 18, 333-342.	0.4	30
597	CXCL12-Induced Monocyte-Endothelial Interactions Promote Lymphocyte Transmigration Across an in Vitro Blood-Brain Barrier. <i>Science Translational Medicine</i> , 2012, 4, 119ra14.	5.8	65
598	Accelerated and enhanced effect of CCR5-transduced bone marrow neural stem cells on autoimmune encephalomyelitis. <i>Acta Neuropathologica</i> , 2012, 124, 491-503.	3.9	34
599	CCR5 deficiency does not reduce hypertensive end-organ damage in mice. <i>American Journal of Hypertension</i> , 2012, 25, 479-486.	1.0	20
600	Rosiglitazone attenuates the age-related changes in astrocytosis and the deficit in LTP. <i>Neurobiology of Aging</i> , 2012, 33, 162-175.	1.5	51
601	Pharmacological characterization of a small-molecule agonist for the chemokine receptor CXCR3. <i>British Journal of Pharmacology</i> , 2012, 166, 898-911.	2.7	44
602	Current status of chemokine receptor inhibitors in development. <i>Immunology Letters</i> , 2012, 145, 68-78.	1.1	55
603	Dissection of inflammatory processes using chemokine biology: Lessons from clinical models. <i>Immunology Letters</i> , 2012, 145, 55-61.	1.1	4
604	Protein expression profiling of inflammatory mediators in human temporal lobe epilepsy reveals co-activation of multiple chemokines and cytokines. <i>Journal of Neuroinflammation</i> , 2012, 9, 207.	3.1	61

#	ARTICLE	IF	CITATIONS
605	RANTES-mediated control of excitatory amino acid release in mouse spinal cord. <i>Journal of Neurochemistry</i> , 2012, 121, 428-437.	2.1	42
606	Role of CCR2 in immunobiology and neurobiology. <i>Clinical and Experimental Neuroimmunology</i> , 2012, 3, 16-29.	0.5	25
607	Immunological Mechanisms. , 2012, , 165-189.		0
608	IFN- $\beta$ -induced apoptosis of human embryonic stem cell derived oligodendrocyte progenitor cells is restricted by CXCR2 signaling. <i>Stem Cell Research</i> , 2012, 9, 208-217.	0.3	27
609	INF- $\gamma$ 1b therapy modulates l-arginine and nitric oxide metabolism in patients with relapse remittent multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2012, 323, 187-192.	0.3	17
610	Initiation and Regulation of CNS Autoimmunity: Balancing Immune Surveillance and Inflammation in the CNS. <i>Neuroscience and Medicine</i> , 2012, 03, 203-224.	0.2	5
611	An Autoimmune Phenotype in Vulvar Lichen Sclerosus and Lichen Planus: A Th1 Response and High Levels of MicroRNA-155. <i>Journal of Investigative Dermatology</i> , 2012, 132, 658-666.	0.3	123
612	A Novel Highly Potent Therapeutic Antibody Neutralizes Multiple Human Chemokines and Mimics Viral Immune Modulation. <i>PLoS ONE</i> , 2012, 7, e43332.	1.1	7
613	Immunomodulatory Effects of Liriope Platyphylla Water Extract on Lipopolysaccharide-Activated Mouse Macrophage. <i>Nutrients</i> , 2012, 4, 1887-1897.	1.7	17
614	Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients. <i>Pharmacogenomics</i> , 2012, 13, 43-53.	0.6	25
615	Chemokines in CNS injury and repair. <i>Cell and Tissue Research</i> , 2012, 349, 229-248.	1.5	132
616	Discovery of potent and specific CXCR3 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 357-362.	1.0	19
617	CCR5 blockade is well tolerated and induces changes in the tissue distribution of CCR5+ and CD25+ T cells in healthy, SIV-uninfected rhesus macaques. <i>Journal of Medical Primatology</i> , 2012, 41, 24-42.	0.3	7
618	Targeting chemokine receptors in chronic inflammatory diseases: An extensive review. , 2012, 133, 1-18.		112
619	Characterization of Th1- and Th2-associated Chemokine Receptor Expression in Spleens of Patients with Immune Thrombocytopenia. <i>Journal of Clinical Immunology</i> , 2013, 33, 938-946.	2.0	7
620	T cell-mediated experimental autoimmune encephalomyelitis is CXCR3 independent. <i>European Journal of Immunology</i> , 2013, 43, 2866-2874.	1.6	24
621	Matrine suppresses expression of adhesion molecules and chemokines as a mechanism underlying its therapeutic effect in CNS autoimmunity. <i>Immunologic Research</i> , 2013, 56, 189-196.	1.3	42
622	CCL5-glutamate interaction in central nervous system: Early and acute presynaptic defects in EAE mice. <i>Neuropharmacology</i> , 2013, 75, 337-346.	2.0	25

#	ARTICLE	IF	CITATIONS
624	Decreased pain responses of C chemokine receptor 5 knockout mice to chemical or inflammatory stimuli. <i>Neuropharmacology</i> , 2013, 67, 57-65.	2.0	36
625	Differential expression profile of Th1/Th17/Th2-related chemokines and their receptors in patients with acquired bone marrow failure syndromes. <i>Human Immunology</i> , 2013, 74, 176-180.	1.2	12
626	Expression of CXCR3 and its ligands CXCL9, -10 and -11 in paediatric opsoclonus-myoclonus syndrome. <i>Clinical and Experimental Immunology</i> , 2013, 172, 427-436.	1.1	21
627	Concise Review: Immunological Properties of Ocular Surface and Importance of Limbal Stem Cells for Transplantation. <i>Stem Cells Translational Medicine</i> , 2013, 2, 614-624.	1.6	14
628	Neutralizing Nanobodies Targeting Diverse Chemokines Effectively Inhibit Chemokine Function. <i>Journal of Biological Chemistry</i> , 2013, 288, 25173-25182.	1.6	40
629	Vitamin D Receptor Agonists Target CXCL10: New Therapeutic Tools for Resolution of Inflammation. <i>Mediators of Inflammation</i> , 2013, 2013, 1-11.	1.4	55
630	Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression. <i>Multiple Sclerosis Journal</i> , 2013, 19, 577-584.	1.4	41
631	Multiple Sclerosis, Relapses, and the Mechanism of Action of Adrenocorticotrophic Hormone. <i>Frontiers in Neurology</i> , 2013, 4, 21.	1.1	39
632	Design and Synthesis of Tri-substituted Chiral Pyrrolidin-2-one Derivatives as CCR4 Antagonists. <i>Chinese Journal of Chemistry</i> , 2013, 31, n/a-n/a.	2.6	3
633	Increase of Interferon- $\gamma$ Inducible CXCL9 and CXCL11 Serum Levels in Patients with Active Graves' Disease and Modulation by Methimazole Therapy. <i>Thyroid</i> , 2013, 23, 1461-1469.	2.4	18
634	Role of CXCL10 in central nervous system inflammation. <i>International Journal of Interferon, Cytokine and Mediator Research</i> , 0, 1.	1.1	24
636	The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention. <i>Journal of Neuroimmunology</i> , 2014, 277, 153-159.	1.1	26
637	The chemokine receptor CCR5 $\gamma$ 32 allele in natalizumab-treated multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2014, 129, 27-31.	1.0	9
638	Chemokine receptors on T cells in multiple sclerosis. <i>Clinical and Experimental Neuroimmunology</i> , 2014, 5, 162-174.	0.5	4
639	Circulating dendritic cells of multiple sclerosis patients are proinflammatory and their frequency is correlated with MS-associated genetic risk factors. <i>Multiple Sclerosis Journal</i> , 2014, 20, 548-557.	1.4	31
640	Immunophenotyping of Cerebrospinal Fluid Cells in Multiple Sclerosis. <i>JAMA Neurology</i> , 2014, 71, 905.	4.5	54
641	The Transcription Factor IRF8 Activates Integrin-Mediated TGF- $\beta$ 2 Signaling and Promotes Neuroinflammation. <i>Immunity</i> , 2014, 40, 187-198.	6.6	111
642	Low DPP4 expression and activity in multiple sclerosis. <i>Clinical Immunology</i> , 2014, 150, 170-183.	1.4	34

#	ARTICLE	IF	CITATIONS
643	Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE models. <i>Inflammopharmacology</i> , 2014, 22, 1-22.	1.9	98
644	GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics. <i>Trends in Pharmacological Sciences</i> , 2014, 35, 247-255.	4.0	79
646	Advances in understanding the pathogenesis of autoimmune disorders: focus on chemokines and lymphocyte trafficking. <i>British Journal of Haematology</i> , 2014, 164, 329-341.	1.2	27
647	DARC shuttles inflammatory chemokines across the blood-brain barrier during autoimmune central nervous system inflammation. <i>Brain</i> , 2014, 137, 1454-1469.	3.7	59
648	Pathology of multiple sclerosis and related inflammatory demyelinating diseases. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 122, 15-58.	1.0	231
649	Exploring the CXCR3 Chemokine Receptor with Small-Molecule Antagonists and Agonists. <i>Topics in Medicinal Chemistry</i> , 2014, , 119-185.	0.4	6
650	Acute desipramine restores presynaptic cortical defects in murine experimental autoimmune encephalomyelitis by suppressing central CCL5 overproduction. <i>British Journal of Pharmacology</i> , 2014, 171, 2457-2467.	2.7	19
651	Characterization and expression analysis of an interferon- $\gamma$ induced chemokine receptor CXCR3 in common carp ( <i>Cyprinus carpio</i> L.). <i>Developmental and Comparative Immunology</i> , 2014, 47, 68-76.	1.0	21
652	Deletion of astroglial CXCL10 delays clinical onset but does not affect progressive axon loss in a murine autoimmune multiple sclerosis model. <i>Journal of Neuroinflammation</i> , 2014, 11, 105.	3.1	65
653	CXCR3 modulates glial accumulation and activation in cuprizone-induced demyelination of the central nervous system. <i>Journal of Neuroinflammation</i> , 2014, 11, 109.	3.1	43
654	Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse. <i>Arthritis Research and Therapy</i> , 2014, 16, R126.	1.6	27
655	Discrepancy in CCL2 and CCR2 expression in white versus grey matter hippocampal lesions of Multiple Sclerosis patients. <i>Acta Neuropathologica Communications</i> , 2014, 2, 98.	2.4	32
656	Demyelination during multiple sclerosis is associated with combined activation of microglia/macrophages by IFN- $\gamma$ and alpha B-crystallin. <i>Acta Neuropathologica</i> , 2014, 128, 215-229.	3.9	73
657	Cladribine exerts an immunomodulatory effect on human and murine dendritic cells. <i>International Immunopharmacology</i> , 2014, 18, 347-357.	1.7	28
658	Pleural fluid mononuclear cells (PFMCs) from tuberculous pleurisy can migrate in vitro in response to CXCL10. <i>Tuberculosis</i> , 2014, 94, 123-130.	0.8	3
659	Genetics of primary progressive multiple sclerosis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 122, 211-230.	1.0	17
660	MOG extracellular domain (p125) triggers elevated frequency of CXCR3+ CD4+ Th1 cells in the CNS of mice and induces greater incidence of severe EAE. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1312-1321.	1.4	11
661	Chemokines and chemokine receptors: Update on utility and challenges for the clinician. <i>Surgery</i> , 2014, 155, 961-973.	1.0	55

#	ARTICLE	IF	CITATIONS
662	“Neuroinflammation” differs categorically from inflammation: transcriptomes of Alzheimer's disease, Parkinson's disease, schizophrenia and inflammatory diseases compared. <i>Neurogenetics</i> , 2014, 15, 201-212.	0.7	55
663	The Biological Functions, Structure and Sources of CXCL10 and Its Outstanding Part in the Pathophysiology of Multiple Sclerosis. <i>NeuroImmunoModulation</i> , 2014, 21, 322-330.	0.9	115
664	Biomarkers for Multiple Sclerosis. <i>Internal Medicine</i> , 2014, 53, 361-365.	0.3	36
665	A destructive feedback loop mediated by CXCL 10 in central nervous system inflammatory disease. <i>Annals of Neurology</i> , 2015, 78, 619-629.	2.8	26
666	18 $\beta$ -glycyrretinic acid suppresses experimental autoimmune encephalomyelitis through inhibition of microglia activation and promotion of remyelination. <i>Scientific Reports</i> , 2015, 5, 13713.	1.6	43
667	Human mesenchymal stem cells target adhesion molecules and receptors involved in T cell extravasation. <i>Stem Cell Research and Therapy</i> , 2015, 6, 245.	2.4	21
668	The Ins and Outs of B Cells in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2015, 6, 565.	2.2	54
669	Computational Modelling Approaches on Epigenetic Factors in Neurodegenerative and Autoimmune Diseases and Their Mechanistic Analysis. <i>Journal of Immunology Research</i> , 2015, 2015, 1-10.	0.9	11
670	Plasma Biomarkers Discriminate Clinical Forms of Multiple Sclerosis. <i>PLoS ONE</i> , 2015, 10, e0128952.	1.1	40
671	Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway. <i>International Journal of Molecular Sciences</i> , 2015, 16, 13885-13907.	1.8	107
672	Sex-specific association of RANTES gene $\gamma$ 403 variant in Meniere's disease. <i>European Archives of Oto-Rhino-Laryngology</i> , 2015, 272, 2221-2225.	0.8	6
673	Fingolimod induces neuroprotective factors in human astrocytes. <i>Journal of Neuroinflammation</i> , 2015, 12, 184.	3.1	70
674	Ligand-Biased and Probe-Dependent Modulation of Chemokine Receptor CXCR3 Signaling by Negative Allosteric Modulators. <i>ChemMedChem</i> , 2015, 10, 566-574.	1.6	17
675	Dynamic Changes of Microglia/Macrophage $M_1$ and $M_2$ Polarization in Theiler's Murine Encephalomyelitis. <i>Brain Pathology</i> , 2015, 25, 712-723.	2.1	41
676	CXCL10 Triggers Early Microglial Activation in the Cuprizone Model. <i>Journal of Immunology</i> , 2015, 194, 3400-3413.	0.4	115
677	Common variants of chemokine receptor gene CXCR3 and its ligands CXCL10 and CXCL11 associated with vascular permeability of dengue infection in peninsular Malaysia. <i>Human Immunology</i> , 2015, 76, 421-426.	1.2	6
678	Control of autoimmune CNS inflammation by astrocytes. <i>Seminars in Immunopathology</i> , 2015, 37, 625-638.	2.8	152
679	Chemokine biomarkers in central nervous system tissue and cerebrospinal fluid in the Theiler's virus model mirror those in multiple sclerosis. <i>Cytokine</i> , 2015, 76, 577-580.	1.4	10

#	ARTICLE	IF	CITATIONS
680	Matrine ameliorates experimental autoimmune encephalomyelitis by modulating chemokines and their receptors. <i>Experimental and Molecular Pathology</i> , 2015, 99, 212-219.	0.9	17
681	Bioenergetics profile of CD4 + T cells in relapsing remitting multiple sclerosis subjects. <i>Journal of Biotechnology</i> , 2015, 202, 31-39.	1.9	41
682	The role of chemokines in adjusting the balance between CD4+ effector T cell subsets and FOXP3-negative regulatory T cells. <i>International Immunopharmacology</i> , 2015, 28, 829-835.	1.7	19
683	Brain endothelial dysfunction in cerebral adrenoleukodystrophy. <i>Brain</i> , 2015, 138, 3206-3220.	3.7	61
684	Identifying Modulators of CXC Receptors 3 and 4 with Tailored Selectivity Using Multi-Target Docking. <i>ACS Chemical Biology</i> , 2015, 10, 715-724.	1.6	36
685	Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2016, 13, 207.	3.1	127
686	Impact of Exercise on Innate Immunity in Multiple Sclerosis Progression and Symptomatology. <i>Frontiers in Physiology</i> , 2016, 7, 194.	1.3	25
687	EphrinB1 and EphrinB2 regulate T cell chemotaxis and migration in experimental autoimmune encephalomyelitis and multiple sclerosis. <i>Neurobiology of Disease</i> , 2016, 91, 292-306.	2.1	24
688	Immune Activation and HIV-Specific CD8+ T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 791-800.	0.5	11
689	Neuropilin-1 modulates interferon- $\beta$ -stimulated signaling in brain microvascular endothelial cells. <i>Journal of Cell Science</i> , 2016, 129, 3911-3921.	1.2	32
690	Dynamic Response Genes in CD4+ T Cells Reveal a Network of Interactive Proteins that Classifies Disease Activity in Multiple Sclerosis. <i>Cell Reports</i> , 2016, 16, 2928-2939.	2.9	38
691	Gatekeeper role of brain antigen-presenting CD11c <sup>+</sup> cells in neuroinflammation. <i>EMBO Journal</i> , 2016, 35, 89-101.	3.5	59
692	The impact of multiple sclerosis relapse treatment on migration of effector T cells – Preliminary study. <i>Neurologia i Neurochirurgia Polska</i> , 2016, 50, 155-162.	0.6	3
693	The expression of the chemokine receptor CCR5 in tick-borne encephalitis. <i>Journal of Neuroinflammation</i> , 2016, 13, 45.	3.1	29
694	CXCR4 and NMDA Receptors Are Functionally Coupled in Rat Hippocampal Noradrenergic and Glutamatergic Nerve Endings. <i>Journal of Neuroimmune Pharmacology</i> , 2016, 11, 645-656.	2.1	21
695	CCR5 blockade for neuroinflammatory diseases – beyond control of HIV. <i>Nature Reviews Neurology</i> , 2016, 12, 95-105.	4.9	109
696	RANTES correlates with inflammatory activity and synaptic excitability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1405-1412.	1.4	46
697	Sphingosine 1-phosphate signaling in astrocytes: Implications for progressive multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2016, 361, 60-65.	0.3	25



#	ARTICLE	IF	CITATIONS
698	CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders: A systematic review. <i>Cytokine</i> , 2016, 77, 227-237.	1.4	209
699	T-bet promotes the accumulation of encephalitogenic Th17 cells in the CNS. <i>Journal of Neuroimmunology</i> , 2017, 304, 35-39.	1.1	5
700	Role of Oligodendrocyte Dysfunction in Demyelination, Remyelination and Neurodegeneration in Multiple Sclerosis. <i>Advances in Experimental Medicine and Biology</i> , 2017, 958, 91-127.	0.8	88
701	Influenza virus infection exacerbates experimental autoimmune encephalomyelitis disease by promoting type I T cells infiltration into central nervous system. <i>Journal of Autoimmunity</i> , 2017, 77, 1-10.	3.0	28
702	Cytokines and Chemokines. , 2017, , 261-283.		1
703	Altered expression of CXCR3 and CCR6 and their ligands in HTLV-1 carriers and HAM/TSP patients. <i>Journal of Medical Virology</i> , 2017, 89, 1461-1468.	2.5	11
704	Neurophysiology of synaptic functioning in multiple sclerosis. <i>Clinical Neurophysiology</i> , 2017, 128, 1148-1157.	0.7	50
705	LRCH1 interferes with DOCK8-Cdc42-induced T cell migration and ameliorates experimental autoimmune encephalomyelitis. <i>Journal of Experimental Medicine</i> , 2017, 214, 209-226.	4.2	40
706	Designing small molecule CXCR3 antagonists. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 159-168.	2.5	21
707	Natural and induced immunization against CCL20 ameliorate experimental autoimmune encephalitis and may confer protection against multiple sclerosis. <i>Clinical Immunology</i> , 2017, 183, 316-324.	1.4	6
708	Protein Tyrosine Phosphatase Inhibition Prevents Experimental Cerebral Malaria by Precluding CXCR3 Expression on T Cells. <i>Scientific Reports</i> , 2017, 7, 5478.	1.6	3
709	Pharmacologic characterizations of a P2X7 receptor-specific radioligand, [11C]GSK1482160 for neuroinflammatory response. <i>Nuclear Medicine Communications</i> , 2017, 38, 372-382.	0.5	57
710	Abnormalities in chemokine levels in schizophrenia and their clinical correlates. <i>Schizophrenia Research</i> , 2017, 181, 63-69.	1.1	71
711	Chemokine-Driven CD4 + T Cell Homing: New Concepts and Recent Advances. <i>Advances in Immunology</i> , 2017, 135, 119-181.	1.1	18
712	CCL5-Glutamate Cross-Talk in Astrocyte-Neuron Communication in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2017, 8, 1079.	2.2	56
713	The Role of the Central Nervous System Microenvironment in Pediatric Acute Lymphoblastic Leukemia. <i>Frontiers in Pediatrics</i> , 2017, 5, 90.	0.9	21
714	Docking Studies for Multi-Target Drugs. <i>Current Drug Targets</i> , 2017, 18, 592-604.	1.0	39
715	Chemokines in homeostasis and diseases. <i>Cellular and Molecular Immunology</i> , 2018, 15, 324-334.	4.8	126



#	ARTICLE	IF	CITATIONS
716	Sphingosine 1-phosphate receptors regulate TLR4-induced CXCL5 release from astrocytes and microglia. <i>Journal of Neurochemistry</i> , 2018, 144, 736-747.	2.1	64
717	To the Brain and Back: Migratory Paths of Dendritic Cells in Multiple Sclerosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 178-192.	0.9	42
718	Molecular Mechanisms of Biased and Probe-Dependent Signaling at CXC-Motif Chemokine Receptor CXCR3 Induced by Negative Allosteric Modulators. <i>Molecular Pharmacology</i> , 2018, 93, 309-322.	1.0	8
719	Disruption of CXCR3 function impedes the development of Sjögren's syndrome-like xerostomia in non-obese diabetic mice. <i>Laboratory Investigation</i> , 2018, 98, 620-628.	1.7	18
720	CCR7 on CD4+ T Cells Plays a Crucial Role in the Induction of Experimental Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2018, 200, 2554-2562.	0.4	30
721	Palm Fruit Bioactives modulate human astrocyte activity in vitro altering the cytokine secretome reducing levels of TNF $\alpha$ , RANTES and IP-10. <i>Scientific Reports</i> , 2018, 8, 16423.	1.6	17
722	Innate Immunity Cells and the Neurovascular Unit. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3856.	1.8	38
723	Differences in Intercellular Communication During Clinical Relapse and Gadolinium-Enhanced MRI in Patients With Relapsing Remitting Multiple Sclerosis: A Study of the Composition of Extracellular Vesicles in Cerebrospinal Fluid. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 418.	1.8	35
724	Metabotropic Glutamate Receptors in Glial Cells: A New Potential Target for Neuroprotection?. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 414.	1.4	79
725	B cells from patients with multiple sclerosis have a pathogenic phenotype and increased LT $\alpha$ and TGF $\beta$ 1 response. <i>Journal of Neuroimmunology</i> , 2018, 324, 157-164.	1.1	18
726	The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review. <i>Frontiers in Immunology</i> , 2018, 9, 2056.	2.2	67
727	Shuttling Tolerogenic Dendritic Cells across the Blood-Brain Barrier In Vitro via the Introduction of De Novo C $\alpha$ C Chemokine Receptor 5 Expression Using Messenger RNA Electroporation. <i>Frontiers in Immunology</i> , 2018, 8, 1964.	2.2	8
728	The Expanding Therapeutic Perspective of CCR5 Blockade. <i>Frontiers in Immunology</i> , 2017, 8, 1981.	2.2	83
729	The Role of Astrocytes in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2018, 9, 217.	2.2	242
730	Adenosine A2A receptor blockade attenuates spatial memory deficit and extent of demyelination areas in lyolecithin-induced demyelination model. <i>Life Sciences</i> , 2018, 205, 63-72.	2.0	14
731	Animal Models of Multiple Sclerosis. , 2018, , 37-72.		6
732	Roles of Macrophages and Astrocytes in Pathogenesis of Multiple Sclerosis. , 2018, , 517-528.		1
733	Chemokine CXCL10 and Coronavirus-Induced Neurologic Disease. <i>Viral Immunology</i> , 2019, 32, 25-37.	0.6	42

#	ARTICLE	IF	CITATIONS
734	Theiler's murine encephalomyelitis virus infection of astrocytes induces the expression of chemokines which attract activated but not resting T lymphocytes. <i>Journal of NeuroVirology</i> , 2019, 25, 844-852.	1.0	0
735	Entanglement of CCR5 and Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 209.	1.7	21
736	Human immunodeficiency virus and multiple sclerosis: a review of the literature. <i>Neurological Research and Practice</i> , 2019, 1, 24.	1.0	9
737	IP-10 and MCP-1 gene polymorphisms in Chinese patients with chronic immune thrombocytopenia. <i>Autoimmunity</i> , 2019, 52, 235-241.	1.2	0
738	Human CCR5 <sup>high</sup> effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis. <i>Brain</i> , 2019, 142, 3411-3427.	3.7	39
739	IP-10 contributes to the inhibition of mycobacterial growth in an ex vivo whole blood assay. <i>International Journal of Medical Microbiology</i> , 2019, 309, 299-306.	1.5	14
740	RIP1 kinase inhibitor halts the progression of an immune-induced demyelination disease at the stage of monocyte elevation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 5675-5680.	3.3	32
741	The contribution of astrocytes to the neuroinflammatory response in multiple sclerosis and experimental autoimmune encephalomyelitis. <i>Acta Neuropathologica</i> , 2019, 137, 757-783.	3.9	160
742	Influence of different rehabilitative aerobic exercise programs on (anti-) inflammatory immune signalling, cognitive and functional capacity in persons with MS – study protocol of a randomized controlled trial. <i>BMC Neurology</i> , 2019, 19, 37.	0.8	19
743	CSF Cytokines in Aging, Multiple Sclerosis, and Dementia. <i>Frontiers in Immunology</i> , 2019, 10, 480.	2.2	91
744	Th17 T lymphocytes in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2019, 330, 67-73.	1.1	11
745	Designing an improved T-cell mobilising CXCL10 mutant through enhanced GAG binding affinity. <i>Protein Engineering, Design and Selection</i> , 2019, 32, 367-373.	1.0	2
746	CCR5-Positive Inflammatory Monocytes are Crucial for Control of Sepsis. <i>Shock</i> , 2019, 52, e100-e106.	1.0	12
747	Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases. <i>Journal of Neuroinflammation</i> , 2019, 16, 219.	3.1	96
749	CXCR3+ T cells in multiple sclerosis correlate with reduced diversity of the gut microbiome. <i>Journal of Translational Autoimmunity</i> , 2020, 3, 100032.	2.0	32
750	CNS Macrophages and Infant Infections. <i>Frontiers in Immunology</i> , 2020, 11, 2123.	2.2	7
751	The combination of C C chemokine receptor type 5 (CCR5) and Treg cells predicts prognosis in patients with ischemic stroke. <i>Journal of Neuroimmunology</i> , 2020, 349, 577404.	1.1	10
752	Fibrinogen and Neuroinflammation During Traumatic Brain Injury. <i>Molecular Neurobiology</i> , 2020, 57, 4692-4703.	1.9	24

#	ARTICLE	IF	CITATIONS
753	CCL-11 or Eotaxin-1: An Immune Marker for Ageing and Accelerated Ageing in Neuro-Psychiatric Disorders. <i>Pharmaceuticals</i> , 2020, 13, 230.	1.7	39
754	Perivascular tissue resident memory T cells as therapeutic target in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 835-848.	1.4	13
755	Soluble PD1 levels are increased with disease activity in paediatric onset autoimmune hepatitis and inflammatory bowel disease. <i>Autoimmunity</i> , 2020, 53, 253-260.	1.2	9
756	Tissue-resident memory T cells invade the brain parenchyma in multiple sclerosis white matter lesions. <i>Brain</i> , 2020, 143, 1714-1730.	3.7	131
757	Inflammation-related plasma and CSF biomarkers for multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 12952-12960.	3.3	102
758	The role of chemokines and chemokine receptors in multiple sclerosis. <i>International Immunopharmacology</i> , 2020, 83, 106314.	1.7	69
759	Clozapine reduces infiltration into the CNS by targeting migration in experimental autoimmune encephalomyelitis. <i>Journal of Neuroinflammation</i> , 2020, 17, 53.	3.1	21
760	Environmental Influencers, MicroRNA, and Multiple Sclerosis. <i>Journal of Central Nervous System Disease</i> , 2020, 12, 117957351989495.	0.7	22
761	Maraviroc attenuates the pathogenesis of experimental autoimmune encephalitis. <i>International Immunopharmacology</i> , 2020, 80, 106138.	1.7	23
762	HIV and opiates dysregulate K <sup>+</sup> -Cl <sup>-</sup> cotransporter 2 (KCC2) to cause GABAergic dysfunction in primary human neurons and Tat-transgenic mice. <i>Neurobiology of Disease</i> , 2020, 141, 104878.	2.1	18
763	Association of <i>VEGFA</i> , <i>TIMP-3</i> , and <i>IL-6</i> gene polymorphisms with predisposition to optic neuritis and optic neuritis with multiple sclerosis. <i>Ophthalmic Genetics</i> , 2021, 42, 35-44.	0.5	1
764	Altered astrocytic function in experimental neuroinflammation and multiple sclerosis. <i>Glia</i> , 2021, 69, 1341-1368.	2.5	24
765	Attenuated immune control of Epstein-Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA-DR15. <i>European Journal of Immunology</i> , 2021, 51, 64-75.	1.6	53
766	Cytokines and Chemokines in SARS-CoV-2 Infections—Therapeutic Strategies Targeting Cytokine Storm. <i>Biomolecules</i> , 2021, 11, 91.	1.8	67
767	A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis. <i>Metabolic Brain Disease</i> , 2021, 36, 375-406.	1.4	17
768	Astrocyte-specific expression of interleukin 23 leads to an aggravated phenotype and enhanced inflammatory response with B cell accumulation in the EAE model. <i>Journal of Neuroinflammation</i> , 2021, 18, 101.	3.1	19
769	Rg1 exerts protective effect in CPZ-induced demyelination mouse model via inhibiting CXCL10-mediated glial response. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 563-576.	2.8	6
770	TNFR2 Signaling Regulates the Immunomodulatory Function of Oligodendrocyte Precursor Cells. <i>Cells</i> , 2021, 10, 1785.	1.8	17

#	ARTICLE	IF	CITATIONS
771	RANTES/CCL5 Signaling from Jawbone Cavitations to Epistemology of Multiple Sclerosis â€“ Research and Case Studies. Degenerative Neurological and Neuromuscular Disease, 2021, Volume 11, 41-50.	0.7	6
772	PET Imaging Radiotracers of Chemokine Receptors. Molecules, 2021, 26, 5174.	1.7	8
773	Neuroinflammatory astrocyte subtypes in the mouse brain. Nature Neuroscience, 2021, 24, 1475-1487.	7.1	285
774	Multiple Sclerosis Is an Inflammatory T-Cellâ€“Mediated Autoimmune Disease. Archives of Neurology, 2004, 61, 1613.	4.9	238
776	Mesenchymal stem cells instruct a beneficial phenotype in reactive astrocytes. Glia, 2021, 69, 1204-1215.	2.5	9
777	T-Cells in Multiple Sclerosis. Results and Problems in Cell Differentiation, 2009, 51, 75-98.	0.2	21
778	Multiple Sclerosis and Autoimmune Encephalomyelitis. , 2007, , 373-404.		1
780	Alcoholâ€“Chemokine Interaction and Neurotransmission. , 2013, , 387-424.		2
781	Cytokine and Cytokine Receptor Genes in the Susceptibility and Resistance to Organ-Specific Autoimmune Diseases. Advances in Experimental Medicine and Biology, 2003, 520, 33-65.	0.8	4
782	Chemokines in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. Advances in Experimental Medicine and Biology, 2003, 520, 120-132.	0.8	21
783	Analysis of CXCR3 and Atypical Variant Expression and Signalling in Human T Lymphocytes. Methods in Molecular Biology, 2010, 616, 125-147.	0.4	2
784	Inflammatory Macrophage Migration in Experimental Autoimmune Encephalomyelitis. Methods in Molecular Biology, 2013, 1013, 161-169.	0.4	3
785	Phage Interaction with the Mammalian Immune System. , 2019, , 91-122.		6
786	Inflammation and Immunity. , 2017, , 161-195.		2
787	Functional Diversity of Chemokines and Chemokine Receptors in Response to Viral Infection of the Central Nervous System. Current Topics in Microbiology and Immunology, 2006, 303, 1-27.	0.7	20
788	HIV Neuropathogenesis. , 2000, , 3-10.		3
789	Chemokine Receptors on Mononuclear Phagocytes in the Central Nervous System of Patients with Multiple Sclerosis. , 2002, , 193-211.		3
790	Neuronal SLC (CCL21) Expression: Implications for the Neuron-Microglial Signaling System. , 2002, , 45-60.		4

#	ARTICLE	IF	CITATIONS
791	Markers of Central Nervous System Glia and Neurons In Vivo During Normal and Pathological Conditions. <i>Current Topics in Microbiology and Immunology</i> , 2002, 265, 119-140.	0.7	15
792	Current status of CCR1 antagonists in clinical trials. , 2007, , 103-113.		2
793	Dendritic cells in the central nervous system. , 2001, , 371-cp1.		2
794	Chemokines. , 2002, , 65-85.		3
795	Chemokine Receptor Signal Transduction. , 2002, , 99-117.		1
796	Chemokine Responses in Virus-Induced Neurologic Disease. , 2002, , 191-202.		2
797	Insights from Transgenic and Knockout Mice. , 2002, , 225-233.		1
798	Chemokines and Chemokine Receptors in Multiple Sclerosis. , 2002, , 317-332.		2
800	Expression of the interferon- $\beta$ -inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. <i>Neuropathology and Applied Neurobiology</i> , 2000, 26, 133-142.	1.8	195
801	Adenovirus-Mediated Expression of CXCL10 in the Central Nervous System Results in T-Cell Recruitment and Limited Neuropathology. <i>Journal of NeuroVirology</i> , 2003, 9, 315-324.	1.0	1
802	DIFFERENTIAL EXPRESSION OF CHEMOKINES AND CHEMOKINE RECEPTORS SHAPES THE INFLAMMATORY RESPONSE IN REJECTING HUMAN LIVER TRANSPLANTS <sup>1</sup> . <i>Transplantation</i> , 2001, 72, 1957-1967.	0.5	122
803	Effector pathways in immune mediated central nervous system demyelination. <i>Current Opinion in Neurology</i> , 1999, 12, 323-336.	1.8	52
804	Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 72, 498-502.	0.9	110
805	Antigenicity and immunogenicity of allogeneic retinal transplants. <i>Journal of Clinical Investigation</i> , 2001, 108, 1175-1183.	3.9	10
806	Regulation of pulmonary fibrosis by chemokine receptor CXCR3. <i>Journal of Clinical Investigation</i> , 2004, 114, 291-299.	3.9	276
807	Trafficking of immune cells in the central nervous system. <i>Journal of Clinical Investigation</i> , 2010, 120, 1368-1379.	3.9	426
808	CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. <i>Journal of Clinical Investigation</i> , 2014, 124, 2009-2022.	3.9	145
809	CXC chemokine receptor 3 expression on CD34+hematopoietic progenitors from human cord blood induced by granulocyte-macrophage colony-stimulating factor: chemotaxis and adhesion induced by its ligands, interferon $\beta$ -inducible protein 10 and monokine induced by interferon $\beta$ . <i>Blood</i> , 2000, 96, 1230-1238.	0.6	4

#	ARTICLE	IF	CITATIONS
810	A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection. <i>BMC Immunology</i> , 2012, 13, 2.	0.9	70
811	Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine. <i>Journal of Leukocyte Biology</i> , 2002, 72, 183-191.	1.5	75
812	Function of multiple sclerosis-protective HLA class I alleles revealed by genome-wide protein-quantitative trait loci mapping of interferon signalling. <i>PLoS Genetics</i> , 2020, 16, e1009199.	1.5	12
813	A Combined CXCL10, CXCL8 and H-FABP Panel for the Staging of Human African Trypanosomiasis Patients. <i>PLoS Neglected Tropical Diseases</i> , 2009, 3, e459.	1.3	62
814	Human Astrocytes: Secretome Profiles of Cytokines and Chemokines. <i>PLoS ONE</i> , 2014, 9, e92325.	1.1	303
815	Chemokines in the cerebrospinal fluid of patients with active and stable relapsing-remitting multiple sclerosis. <i>Brazilian Journal of Medical and Biological Research</i> , 2006, 39, 441-445.	0.7	17
816	Obstructive Nephropathy in the Mouse. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1173-1187.	3.0	157
817	CCR5 knockout suppresses experimental autoimmune encephalomyelitis in C57BL/6 mice. <i>Oncotarget</i> , 2016, 7, 15382-15393.	0.8	51
818	CXCL13 CSF level inversely correlates with duration of disease in primary progressive multiple sclerosis. <i>Journal of Medical Science</i> , 2016, 85, 302-304.	0.2	2
819	CXCR3, CXCR5, CXCR6, and CXCR7 in Diabetes. <i>Current Drug Targets</i> , 2016, 17, 515-519.	1.0	18
820	Chemokines and Chemokine Receptors Critical to Host Resistance Following Genital Herpes Simplex Virus Type 2 (HSV-2) Infection. <i>The Open Immunology Journal</i> , 2008, 1, 33-41.	1.5	20
821	Role of microglia in the process of inflammation in the hypoxic developing brain. <i>Frontiers in Bioscience - Scholar</i> , 2011, S3, 884.	0.8	36
822	Chemokines in systemic lupus erythematosus involving the central nervous system. <i>Frontiers in Bioscience - Landmark</i> , 2008, 13, 2527.	3.0	11
823	The contribution of oligodendrocytes and oligodendrocyte progenitor cells to central nervous system repair in multiple sclerosis: perspectives for remyelination therapeutic strategies. <i>Neural Regeneration Research</i> , 2017, 12, 1939.	1.6	35
824	CHEMOKINE RECEPTORS. <i>Biomedical Papers of the Medical Faculty of the University Palacky&amp;#x0301;, Olomouc, Czechoslovakia</i> , 2000, 144, 9-18.	0.2	2
825	The Th1 chemokine IP-10 in Systemic sclerosis. <i>Clinica Terapeutica</i> , 2014, 165, e436-41.	0.2	4
826	Immunotherapeutic Strategies for Multiple Sclerosis. , 2001, , 37-68.		0
827	Differential Patterns of T Cell Chemokine Receptor Expression in Human Th1- and Th2-Associated Diseases. , 2001, , 23-33.		3

#	ARTICLE	IF	CITATIONS
829	Chemokines in the Central Nervous System and Alzheimer's Disease. , 2002, , 333-344.		0
830	Targeting the Chemokine System. Handbook of Experimental Pharmacology, 2003, , 269-294.	0.9	0
831	Preliminary Observations on CC Chemokine Receptor Expression by Mononuclear Phagocytes in Multiple Sclerosis Lesions: Effect of Lesion Heterogeneity. , 2004, , 59-68.		1
832	Chemokines in Coronavirus-Induced Demyelination. , 2005, , 805-820.		0
833	Cytokines and Multiple Sclerosis. , 2005, , 269-298.		0
834	Immunopathogenese. , 2006, , 43-51.		0
836	Polymorphism of chemokine receptor gene CCR5 in multiple sclerosis patients and in healthy subjects in the Siberian region. Bulletin of Siberian Medicine, 2006, 5, 98-104.	0.1	1
837	Review of Novel Immunotherapeutic Strategies for MS. , 2007, , 289-338.		0
840	Estudo dos polimorfismos do gene DUFFY em pacientes com hipertenso maligna e doadores de sangue. Revista Brasileira De Hematologia E Hemoterapia, 2008, 30, .	0.7	0
841	HIV Coreceptors and Their Roles in Leukocyte Trafficking During Neuroinflammatory Diseases. , 2010, , 119-146.		0
842	Screening for simulation peptide specifically binding to the first and the second extracellular domain of CCR5 and its therapeutic effect on mice with autoimmune encephalomyelitis. Academic Journal of Second Military Medical University, 2009, 29, 892-897.	0.0	0
843	Vascular Smooth Muscle Cells Secrete CXCL10 in Response to Heat Shock Protein 90. Journal of Life Science, 2011, 21, 664-670.	0.2	0
844	Lack of Correlation between CCL5 -28C/G Functional Polymorphism and Multiple Sclerosis in Tunisian Patients. Journal of Clinical & Cellular Immunology, 2012, 03, .	1.5	0
846	Immunopathogenese. , 2015, , 39-52.		0
847	CXCR3 and Its Ligands. , 2015, , 1-14.		2
848	CXCR3 and Its Ligands. , 2016, , 404-416.		0
849	CXCL13 CSF level inversely correlates with duration of disease in primary progressive multiple sclerosis. Journal of Medical Science, 2016, 85, 302.	0.2	0
851	Astrocytes in Pathogenesis of Multiple Sclerosis and Potential Translation into Clinic. , 0, , .		1



#	ARTICLE	IF	CITATIONS
854	CXC and CC chemokine receptors on coronary and brain endothelia. <i>Molecular Medicine</i> , 1999, 5, 795-805.	1.9	30
855	Increased Intrathecal Chemokine Receptor CCR2 Expression in Multiple Sclerosis. <i>Biomarker Insights</i> , 2007, 2, 463-8.	1.0	5
857	Ccr2-64i and Ccr5 $\hat{I}^{32}$ Polymorphisms in Patients with Late-Onset Alzheimer's disease; A Study from Iran (Ccr2-64i And Ccr5 $\hat{I}^{32}$ Polymorphisms in Alzheimer's disease). <i>Iranian Journal of Basic Medical Sciences</i> , 2012, 15, 937-44.	1.0	15
858	RGMa regulates CCL5 expression via the BMP receptor in experimental autoimmune encephalomyelitis mice and endothelial cells. <i>Molecular Medicine Reports</i> , 2022, 25, .	1.1	1
859	Astrocytes and Inflammatory T Helper Cells: A Dangerous Liaison in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2022, 13, 824411.	2.2	14
860	Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics. <i>Journal of Neuroinflammation</i> , 2022, 19, 45.	3.1	51
861	Chemokine-Driven Migration of Pro-Inflammatory CD4+ T Cells in CNS Autoimmune Disease. <i>Frontiers in Immunology</i> , 2022, 13, 817473.	2.2	21
862	Effect of Multiple Sclerosis Cerebrospinal Fluid and Oligodendroglia Cell Line Environment on Human Wharton's Jelly Mesenchymal Stem Cells Secretome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2177.	1.8	1
863	Botanically-Derived $\hat{I}^{9}$ -Tetrahydrocannabinol and Cannabidiol, and Their 1:1 Combination, Modulate Toll-like Receptor 3 and 4 Signalling in Immune Cells from People with Multiple Sclerosis. <i>Molecules</i> , 2022, 27, 1763.	1.7	5
864	Artemisinin derivative TPN10466 suppresses immune cell migration and Th1/Th17 differentiation to ameliorate disease severity in experimental autoimmune encephalomyelitis. <i>Cellular Immunology</i> , 2022, 373, 104500.	1.4	7
865	T-cell surveillance of the human brain in health and multiple sclerosis. <i>Seminars in Immunopathology</i> , 2022, 44, 855-867.	2.8	12
866	Targeted blockade of immune mechanisms inhibit B precursor acute lymphoblastic leukemia cell invasion of the central nervous system. <i>Cell Reports Medicine</i> , 2021, 2, 100470.	3.3	3
868	Chemokines and Spinal Cord Injury. , 2008, , 221-233.		0
875	Proteomic Alterations and Novel Markers of Neurotoxic Reactive Astrocytes in Human Induced Pluripotent Stem Cell Models. <i>Frontiers in Molecular Neuroscience</i> , 2022, 15, 870085.	1.4	15
876	Assessing Theoretical Risk and Benefit suggested by Genetic Association Studies of CCR5: Experience in a Drug Development Programme for Maraviroc. <i>Antiviral Therapy</i> , 2007, 12, 233-246.	0.6	35
883	Eotaxin-1 (CCL11) in neuroinflammatory disorders and possible role in COVID-19 neurologic complications. <i>Acta Neurologica Belgica</i> , 2022, 122, 865-869.	0.5	24
884	Evolution, Expression and Functional Analysis of CXCR3 in Neuronal and Cardiovascular Diseases: A Narrative Review. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	17
885	Increased Intrathecal Activity of Follicular Helper T Cells in Patients With Relapsing-Remitting Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	3.1	11

#	ARTICLE	IF	CITATIONS
886	Human Primary Astrocytes Differently Respond to Pro- and Anti-Inflammatory Stimuli. <i>Biomedicines</i> , 2022, 10, 1769.	1.4	9
887	The CCR5 antagonist maraviroc exerts limited neuroprotection without improving neurofunctional outcome in experimental pneumococcal meningitis. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
888	Potential neurotoxic activity of diverse molecules released by astrocytes. <i>Brain Research Bulletin</i> , 2022, 189, 80-101.	1.4	14
889	Development of an Electrochemical CCL5 Chemokine Immunoplatfrom for Rapid Diagnosis of Multiple Sclerosis. <i>Biosensors</i> , 2022, 12, 610.	2.3	3
891	Beta cell and immune cell interactions in autoimmune type 1 diabetes: How they meet and talk to each other. <i>Molecular Metabolism</i> , 2022, 64, 101565.	3.0	5
892	Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19. <i>Computers in Biology and Medicine</i> , 2022, 149, 106029.	3.9	2
893	Inhibition of Th1 activation and differentiation by dietary guar gum ameliorates experimental autoimmune encephalomyelitis. <i>Cell Reports</i> , 2022, 40, 111328.	2.9	9
894	The Immunomodulatory Potential Role of Mesenchymal Stem Cells in Diseases of the Central Nervous System. <i>Neurodegenerative Diseases</i> , 2022, 22, 68-82.	0.8	6
895	Differential transcriptomic changes in the central nervous system and urinary bladders of mice infected with a coronavirus. <i>PLoS ONE</i> , 2022, 17, e0278918.	1.1	2
896	Autoimmune diseases. , 2023, , 123-244.		2
897	Cerebrospinal fluid cytokines after autologous haematopoietic stem cell transplantation and intrathecal rituximab treatment for multiple sclerosis. <i>Brain Communications</i> , 2022, 5, .	1.5	2
898	Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2023, 10, .	3.1	5
899	Transforming the understanding of brain immunity. <i>Science</i> , 2023, 380, .	6.0	42
900	Inflammatory diseases of the CNS. , 2023, , 533-561.		0
903	Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration. <i>Nature Reviews Neurology</i> , 2023, 19, 395-409.	4.9	54
905	Introduction to the neuroimmunology of multiple sclerosis. , 2023, , 1-9.		0
907	Application of Proteomics in the Study of Molecular Markers in Epilepsy. , 2023, , 309-333.		0
909	Astrocytes in human central nervous system diseases: a frontier for new therapies. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	15

#	ARTICLE	IF	CITATIONS
913	Microglial Inflammatory Responses to SARS-CoV-2 Infection: A Comprehensive Review. Cellular and Molecular Neurobiology, 2024, 44, .	1.7	0
914	Astrocytes in Neuroinflammatory and Neurodegenerative Diseases. , 2023, , .		0